BRL 28500 (Clavulanic acid-Ticarcillin) 臨床第一相試験

---(1) 単回筋肉および静脈内投与の検討----

渡辺健太郎・小 山 優・飯 島 福 生 東京共済病院内科

中 沢 久・中 平 和 男 ビーチャム薬品株式会社試験研究所

BRL 28500 は β -lactamase 阻害剤の clavulanic acid (CVA) と ticarcillin (TIPC) との 1:15 の注射用配合製剤である。BRL 28500,potassium clavulanate (CVA-K) 単独 および TIPC 単独 を健康成人男子志願者に投与し、 第一相試験として筋注および静注時の安全性ならびに吸収・排泄に関する検討を行い、次の成績を得た。

- 1. 安全性における副作用の臨床症状として、シリーズ3の CVA-K 0.2g 静注時の1例にむくみを伴う潮紅がみられた。その他には臨床症状および臨床検査値において、薬剤に起因すると思われる異常は認められなかった。
- 2. BRL 28500 0.8 g を筋注したとき,最高血清中濃度は TIPC で 23.20 μ g/ml, CVA では 1.12 μ g/ml であった。また,投与後 8 時間までに投与された TIPC の 69%, CVA の 41% が尿中に回収された。
- 3. BRL 28500 0.8 g, 1.6 g および 3.2 g を静脈内投与したとき、TIPC と CVA の 5 分後の血清中濃度と AUC は用量にほぼ比例し、半減期は用量にかかわらずほとんど同じであった。
- 4. TIPC 単独 3.0 g, CVA-K 単独 0.2 g および BRL 28500 3.2 g を cross over 法で静注したとき、薬剤相互作用は認められなかった。

BRL 28500 は、clavulanic acid (CVA) と ticarcillin (TIPC) を 1:15 (力価比)の比率で配合した注射用抗生物質製剤である (Fig. 1)。 CVA は英国ビーチャム社が開発した β -lactamase 阻害剤で、それ自身の抗菌力は弱く単独で臨床応用することはできないが、耐性菌の産生する β -lactamase (特にベニシリナーゼ型、オキシイミノセファロスポリナーゼ型)と不可逆的に結合し、その酵素活性を永久不活化する 10 。 TIPC はすでに広く臨床に供されており、グラム陽性・陰性菌に対して強い殺菌力を有する penicillin 系抗生物質で忍容性が良好であるため、主として中等度から重度の感染症に使用され、その有用性・安全性が確認されている。

BRL 28500 の 前臨床試験を詳細に 検討した 結果, TIPC とほぼ同等の安全性が推定されたので,予想され る臨床使用量の範囲内で健康成人男子志願者に BRL 28500 とその組成分である TIPC および potassium clavulanate (CVA-K) を投与し,安全性ならびに血清 中濃度,尿中排泄について検討した。


I. 試 験 方 法

1. 対象


被験者は Table 1 に示す男子 34 名で, 平均年齢34.8

歳 (24~50 歳), 平均体重 63.9 kg (50~80 kg), 平均身 長は 169.2 cm (160~178 cm) であった。試験に先だち 志願者は, 投与一週間前に BRL 28500 の皮内反応試験 および末梢血・尿の一般検査, 血液生化学検査, 出血素

Fig. 1 Chemical structures of CVA and TIPC



Potassium clavulanate



Sodium ticarcillin

Table 1 Administration and volunteers

		Table 1 Administra		inteer	
I B 0. II B II 0. II T T 3. III C 0. B 3.	Administration	No./Name	Age (year)	Body weight (kg)	Height (cm)
		1 T.K. 2 H.W.	32 50	59 63	173 174
		3 M.W. 4 S.K.	29 42	63 62	168 167
	I. M.	5 M .T.	26	71	174
I	BRL28500	6 H.I.	30	54	169
	0.8g/2ml (0.5% Lidocaine)	7 K.K.	40	63	170
		8 H.F.	39	64	174
		9 K.S.	32	64	169
		10 Y.S.	28	59	164
		Average	34.8	62.2	170.2
		11 · H.T.	28	65	175
		12 W.S.	30	65	175
		13 T.K.	28	75	166
		14 Y.T.	32	65	169
	I.V.	15 Y.O.	36	71	169
	BRL28500	16 M.M. 17 K.N.	24	50	160
ш	0.8g/10ml (Sterile water) 1.6g/10ml (Sterile water)		33	61	167
	3.2g/10ml (Sterile water)	18 T.T. 19 K.T.	50 37	65 66	168 167
	3.2g/10III (Sterile water)	20 Y.M.	42	55	165
		20 1.M. 21 M.M.	34	65	172
		22 K.S.	41	58	167
		Average	34.6	63.4	168.3
		23 Y.K.	36	78	172
		24 S.K.	26	63	178
		25 K.H.	31	54	165
	I.V.	26 K.T.	30	70	171
	TIPC	27 Y.A.	29	64	172
	3.0g/20ml (Sterile water)	28 M.N.	33	67	173
ш	CVA-K	29 N.A.	42	80	168
	0.2g/20ml (Sterile water) BRL28500	30 S.M.	39	60	168
		31 Y.K.	37	64	163
	3.2g/20ml (Sterile water) (cross over method)	32 Y.T.	44	64	169
ļ	(Cross over method)	33 H.I.	33	64	169
		34 N.H.	40	63	164
		Average	35	65.9	169.3

Table 2 Laboratory findings

1. Haematology	RBC, WBC, Ht, Hb, Platelet, Segmentation, PT, APTT
2. Blood chemistry	GOT, GPT, A1-P, Total bilirubin, Creatinin, Total cholesterol Total protein, A/G ratio, Glucose, ZTT, BUN, Na ⁺ , K ⁺ , Cl ⁻
z. Blood chemistry	Coombs (direct, indirect), CRP, Albumin, Globulin (α_1 , α_2 , γ), CPK*
3. Urinalysis	Spec. gravity, pH, Protein, Glucose, Blood, Sediment (WBC, RBC)
4. Clinical monitoring	Blood pressure, Pulse, Respiration rate, Body temperature, ECG, ESR (1,2hr)
5. Others	General symptoms

^{* :} Only for series 1

Table 3 Laboratory findings in Series I: BRL 28500 (0.8g, IM)

REC					1. 7	Г.К.	2. H	I.W.	3. N	1.W.	4. 5	S.K.
WBC		Items		Normal range	Before	1	Before	1	Before	1	Before	1
WBC		RBC		$476 \pm 60 \times 10^{4} / \text{mm}^{3}$	525	518	452	457	533	539	389	396
Ht		WBC		$63 \pm 21 \times 10^{2} / \text{mm}^{3}$	51	51	60	54	98	108	36	
Hb		Ht		43.4 ± 5.3%	46.0	45.5	42.5	42.5	48.0	48.0	39.5	
Plate		НЬ		15.7 ± 2.0 g/dl	16.4	16.2	14.7	14.4	17.0	16.9	13.7	
State		Platelet		$13\sim35\times10^{4}/\text{mm}^{3}$	22.6	21.6	24.3	25.1	25.9	26.7	18.7	
Lympho 38.7±14.6% 23 29 34 32 29 24 31 75	<i>\(\frac{1}{2} \)</i>		Stab.		4	3	1	2	16	4	8	
Lympho 38.7±14.6% 23 29 34 32 29 24 31 75	Ę.		Seg	$45.1 \pm 15.5\%$	66	54	53	51	48	62	54	
Lympho 38.7±14.6% 23 29 34 32 29 24 31 75	atc	1		$2.7 \pm 4.4\%$	2	8	4	8	0	3	2	7
Lympho 38.7±14.6% 23 29 34 32 29 24 31 75	Ŀ	tation			1	2	1	0	0	1	1	0
Bleeding time	Па						7		7	6	4	5
P.T							34		29	24	31	25
APTT			time		1′00″	1′00″	1'30"	2'30"	2'00"	2′30″	3'00"	1'30"
Fbg										99	85	80
Glucose												
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$												
A G ratio									 			
T.cholesterol 150-250mg/dl 143 167 232 242 193 200 145 134 T.bilirubin 0.1-0.0mg/dl 0.6 0.7 0.6 0.6 0.6 0.8 0.8 0.7 D.bilirubin 0.1-0.5mg/dl 0.2 0.3 0.2 0.2 0.1 0.3 0.3 0.3 L.bilirubin 0.1-0.5mg/dl 0.2 0.3 0.2 0.2 0.1 0.3 0.3 0.3 L.bilirubin 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.5 0.4 ZTT 3-11u 5 5 6 6 5 5 5 5 GOT 5-20u/L 13 10 16 17 9 13 6 15 GPT 2-19u/L 7 8 17 17 7 9 5 12 Al-P 2.7-10K-A 7.4 8.8 10.1 11.8 6.3 6.9 5.0 5.0 BUN 7-22mg/dl 15.6 17.8 13.6 14.4 9.5 8.0 11.9 13.8 EBUN 7-22mg/dl 15.6 17.8 13.6 14.4 9.5 8.0 11.9 13.8 K* 3.5~5.0mEq/L 141 144 142 141 143 144 141 141 K* 3.5~5.0mEq/L 141 144 142 141 143 144 141 141 CI 98~108mEq/L 104 109 106 108 105 106 104 102 Coombs/direct) -		-										
T.bilirubin									-			
Debilirubin 0.1~0.5mg/dl 0.2 0.3 0.2 0.2 0.1 0.3 0.4 0.4 0.4 0.5 0.5 0.5 0.4 0.4 0.5		-										
Libilirubin												
ZTT 3-11u 5 5 6 6 6 5 5 5 5 5				0.1~0.5mg/dl								
GOT 5-20u/L 13 10 16 17 9 13 6 15 GPT 2-19u/L 7 8 17 17 7 9 5 12 BUN 7-22mg/dl 15.6 17.8 13.6 14.4 9.5 8.0 11.9 13.8 Creatinin 0.7~1.3mg/dl 0.7 1.2 0.9 1.2 1.0 1.0 1.0 1.0 0.8 Na* 134-148mEq/L 141 144 142 141 143 140 141 141 K* 3.5~5.0mEq/L 4.1 4.0 4.0 4.7 4.1 4.4 4.3 4.3 CI* 98~108mEq/L 104 109 106 108 105 106 104 102 CRP Albumin 62~72% 70.3 68.5 71.8 69.4 68.3 68.8 73.0 71.1 G1**-globulin 1.8~3.7% 1.2 2.2 1.6 2.5 1.8 2.8 1.6 2.0 G2**-globulin 6.3~10.6% 6.4 6.7 7.7 8.3 9.0 9.7 6.5 6.6 \$\frac{3}{2}\text{globulin 6.1}\text{-10.0%} 6.6 6.6 6.6 7.3 7.9 6.9 6.6 6.4 6.2 \$\frac{7}{2}\text{globulin 9.8}\times20.5% 15.5 16.1 11.7 11.8 13.9 12.2 12.6 14.1 IgG 714-1322mg/dl 969.5 990.9 770.4 764.2 973.9 916.6 777.5 796.2 IgA 87~343mg/dl 260.0 266.4 103.9 106.1 213.2 203.4 203.4 209.1 IgM 41~190mg/dl 119.3 111.6 86.8 81.7 116.3 102.2 208.2 218.5 CPK 5-500/L 42 43 54 74 32 30 39 28 Spec.gravity 1.000~1.030 1.030 1.026 1.030 1.024 1.030 1.025 1.020 1.017 PH 4.8~7.5 6.0 5.0 6.0 5.0 6.0 5.0 6.0 5.0 6.0 5.0 Glucose\phi =			ın	0 11						+		
GPT 2-19u/L · 7 8 17 17 7 9 5 12 Al-P 2.7-10K-A 7.4 8.8 10.1 11.8 6.3 6.9 5.0 5.0 BUN 7-22mg/dl 15.6 17.8 13.6 14.4 9.5 8.0 11.9 13.8 Creatinin 0.7-1.3mg/dl 0.7 1.2 0.9 1.2 1.0 1.0 1.0 0.8 Na* 134-148mEq/L 141 144 142 141 143 140 141 141 K* 3.5-5.0mEq/L 4.1 4.0 4.0 4.7 4.1 4.4 4.3 4.3 4.3 Cl- 98~108mEq/L 104 109 106 108 105 106 104 102 Ccombs(direct) — — — — — — — — — — — — — — — — — — —												
Al-P												
BUN 7~22mg/dl 15.6 17.8 13.6 14.4 9.5 8.0 11.9 13.8												
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	T,	Inches and the second										
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	nist											
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	hen			0.7~1.5mg/di								
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	- G											
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	900											
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	ΒÌ		direct \									
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			direct)									
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$				1								
C2_globulin 6.3~10.6% 6.4 6.7 7.7 8.3 9.0 9.7 6.5 6.6			lin									
Second S												
Yellobulin 9.8~20.5% 15.5 16.1 11.7 11.8 13.9 12.2 12.6 14.1 IgG										 		
IgG												
IgA			111									
IgM				87~343mg/dl								
Spec.gravity												
Spec.gravity			***************************************									
PH		+	vity									
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$												
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		Protein		-~±								
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Sis.	Glucose					_	_				_
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	al,	Blood		-	_	_		_			_	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	ī.	Bilirubin		_			_		_		_	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Ω	Urobilino	ogen	0~2.0mg/day								
RBC 0~4 2~3 2~3 1~2 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 0~1 2~3 2~3 2~3 0~1 2~3 2~3 2~3 0~1 2~3 2~3 2~3 0~1 2~3		Cod	WBC	0~4	1~2	5~9		~~~~				0~1
Blood pressure mmHg 74/104 70/104 80/108 70/98 76/114 72/120 76/112 76/118 Pulse /min. 88 90 68 66 72 63 60 67 Respiration rate /min. 14 16 18 18 18 18 18 18 Body temperature C 36.1 36.4 35.2 35.3 36.0 36.2 36.4 36.6 ECG				0~4								
Pulse /min. 88 90 68 66 72 63 60 67 Respiration rate /min. 14 16 18 18 18 18 18 18 18 18 18 18 18 18 18		Blood pr	essure	mmHg								
Respiration rate /min. 14 16 18 18 18 18 18 18 18 Body temperature C 36.1 36.4 35.2 35.3 36.0 36.2 36.4 36.6 ECG — — — — — — — — — — — — — — — — — — —	oc.			/min.								
ECG	1er:	Respirati	on rate	/min.								
ECG	Ð		nperature	$^{\circ}$	36.1							36.6
ESR(1hr) 1~10/hr 2 4 11 16 10 9 10 9				_	_	_	_			_	_	
		ESR(1hr	•)	1~10/hr	2	4	11	16	10	9	10	9

Table 3-2

	5. N	И.Т.	6.	H.I.	7. F	K.K.	8. I	I.F.	9. I	۲.S.	10.	Y.S.
1 to 1	Before	1week after	Before	1week after	Before	1week after	Before	1week after	Before	1week after	Before	lweek after
	508	473	505	487	431	432	504	495	459	419	488	481
	54	57	58	62	70	62	72	90	49	51	48	58
	47.5	43.5	47.5	45.0	45.0	45.0	48.5	47.5	41.5	38.0	46.0	44.5
	16.6	15.1	16.0	15.6	15.6	15.4	17.1	16.9	14.8	13.5	16.3	15.7
	20.7	21.3	23.1	23.9	17.1	19.2	23.9	24.3	24.4	24.4	24.3	23.2
డుం	39	46	46	3 51	61	10 64	3 45	59	63	47	57	56
atol	5	4	2	3	0	0	2	0	0	1	1	3
Haematology	3	2	1	0	0	0	0	1	2	Û	0	0
Ha	4	9	7	1	5	3	7	6	3	5	3	4
	46	36	38	42	25	23	43	26	24	43	38	37
	3'00"	3'30"	2'00"	2'30"	3'30"	1'00"	3′00″	2'00"	1'30"	3'30"	2'30"	2'00"
	92	88	64	77	64	59	80	77	92	>100	100	>100
	33.7° 195	35.7" 215	39.8"	42.3" 195	34.1" 245	36.8° 273	33.3° 205	34.4° 205	29.4"	30.9° 227	30.8"	32.8" 227
	71	71	67	81	73	80	66	71	71	85	79	91
	8.0	7.6	7.7	7.7	6.7	6.9	7.1	6.9	7.9	7.6	7.5	7.3
	2.17	1.76	2.26	2.39	2.38	2.30	2.40	2.83	1.99	2.27	2.30	2.65
	149	162	172	167	172	182	133	141	149	151	193	189
	0.5	0.7	0.8	0.6	0.3	0.8	0.8	0.7	1.0	0.5	0.4	0.4
	0.2	0.3	0.2	0.4	0.1	0.3	0.3	0.2	0.3	0.2	0.1	0.2
	0.3	0.4	0.6	0.2	0.2	0.5	0.5	0.5	0.7	0.3	0.3	0.2
	16	21	8	10	12	24	8	12	22	19	12	12
	10	10	9	9	10	15	10	13	17	11	11	9
	6.1	6.5	5.6	6.3	7.7	8.4	7.9	8.7	5.1	5.6	5.3	5.4
ž	16.0	13.9	12.9	11.8	18.6	14.8	13.6	11.3	16.1	13.5	13.5	14.6
nistı	0.9	0.9	1.1	1.1	1.2	1.1	0.5	1.1	1.0	1.1	1.1	1.2
hen	3.9	3.7	4.0	139 3.9	3.8	140 4.3	3.9	140 3.8	3.8	142 4.1	142 4.1	141 4.1
d C	104	107	103	108	109	108	106	108	103	111	102	106
Blood chemistry		_	_	_	_	_	_	_	_	_	-	_
щ					_	_		_	_	_	_	
	68.4	63.8	69.3	70.5	70.4	69.7	70.6	73.9	66.6	69.4	69.7	72.6
	7.0	7.0	7.6	2.5 7.7	1.5 8.3	2.4	2.5	1.9	1.4	1.9	1.9	1.9
	6.7	7.4	6.8	6.5	7.2	7.5	7.9	7.3	7.5	7.6 6.1	6.7 8.7	6.9 7.0
	16.6	17.9	14.6	12.8	12.6	10.4	12.9	10.5	16.7	15.1	13.0	11.6
	1278.0	1198.2	1003.3	1009.3	755.1	791.5	777.0	764.4	1186.5	646.3	901.3	876.4
	336.9	310.5	201.6	196.7	113.8	121.7	274.4	281.4	228.7	230.3	268.4	287.2
	74.5	61.2	227.0	191.2	166.4	167.2	196.5	169.7	177.9	149.0	254.2	225.0
	1.025	26 1.030	37	34	69 1.030	54	39	21	50	38	51	54
	6.0	5.0	6.0	5.0	6.0	1.007 5.5	1.030	1.018 6.5	1.020 6.0	1.019 5.0	1.030 6.0	5.0
		±	±		±	-	±	-	-	- 3.0	±	-
ysis			_	_	_	_	_	_	_	_	_	
Urinalysis			_			_		_	_	_	_	
E 5	- 0.1	- 0.1	_					_				_
	0.1	0.1 2~3	0.1	0.1	0.1	0.1	0.1	1.0	0.1	1.0	0.1	1.0
_	0~1	1~2	1~2	1~2 0~1	1~2 2~3	0~1 0~1	5~9 1~2	2~3 1~2	2~3 1~2	1~2	10~19 2~3	1~2 2~3
	78/136	84/140	78/116	70/116	84/118	80/110	84/120	74/124	78/118	80/118	88/120	$\frac{2 \sim 3}{78/112}$
ø	64	72	68	69	66	66	60	75	66	66	72	72
Others	16	18	17	17	17	19	19	17	18	18	18	18
ŏ	36.0	36.0	35.9	36.4	36.2	36.1	36.2	36.5	35.6	36.0	35.8	35.6
	8		6	8	10	12	-	_				
		0		0	10	13	3	3	14	14	5	6

Table 4 Laboratory findings in Series II: BRL28500 (0.8g,1.6g,3.2g, W bolus)

				T	11.	H.T.			12.	W.S.	
				0.8g	1.6g	3.2g		0.8g	1.6g	3.2g	
	It	ems	Normal range	Before	Before	Before	1week after	Before	Before	Before	1week after
-	RBC		$4.76 \pm 60 \times 10^4 / \text{mm}^3$	516	539	517	488	555	567	551	552
	WBC		$63\pm21\times10^{3}/\text{mm}^{3}$	73	79	69	70	49	52	53	54
	Ht		43.4 ± 5.3%	47.0	47.5	47.5	45.0	49.5	50.0	49.5	49.0
	Hb		15.7 ± 2.0g/dl	16.2	16.8	16.3	15.3	16.7	17.1	16.6	16.6
	Platelet		13~35×10 ⁴ /mm ³	23.0	27.9	25.1	25.9	22.6	26.8	24.1	24.4
ğ		Stab.	$8.3 \pm 6.9\%$	9	3	7	10	8	6	3	4
Haematology		Seg.	45.1 ± 15.5%	46	63	48	50	42	47	54	57
nat	Segmen-	Eosino.	2.7±4.4%	. 1.	2	3	2	5	3	3	4
aen	tation	Baso.	$0.8 \pm 1.0\%$	0	0	1	1	0	1	1	0
Ή		Mono.	4.4±2.7%	5	6	5	9	8	2	5	6
		Lympho.	38.7±14.6%	39	26	36	28	37.0	41.0	34	29
	Bleeding	time	1~3min.	3'00"	3'00"	1'30"	3'00"	1'00"	1'00"	1'00"	2'30"
	P.T.		70~130%	77	99	100	100	80	77	85	85
	APTT		(25"~40")	39.8"	38.0"	36.2"	39.4	35.7"	36.5"	37.2	35.5
	Fbg		200~400mg/dl	160	195	227	184	186	205	205	225
	Glucose		60~105mg/dl	73	70	84	72	65	70	77	70
	T.protein		6.6~8.2g/dl	7.0	7.6	7.3	6.9	7.2	7.6	7.3	7.1
	A/G ratio)	1.4~2.4	2.39	3.20	2.35	2.69	2.45	2.66	2.82	2.94
	T.choleste	erol	150~250mg/dl	161	162	155	136	174	175	162	174
	T.bilirubi	n	0.1~1.0mg/dl	0.8	0.8	1.0	0.7	1.8	0.9	1.0	1.1
	D.bilirubi	n	0.1~0.5mg/dl	0.4	0.6	0.5	0.2	0.5	0.3	0.4	0.3
	I.bilirubin			0.4	0.2	0.5	0.5	1.3	0.6	0.6	0.8
	ZTT		3~11u	5	5	5	5	4	4	4	4
	GOT		5~20u/L	8	11	10	6	12	11	9	10
	GPT		2~19u/L	7	8	6	4	11	8	8	6
	Al-P		2.7~10K-A	6.0	7.4	5.4	5.9	5.8	6.8	6.0	6.4
Ţ.	BUN		7~22mg/dl	12.2	12.9	7.3	12.6	16.4	11.8	12.9	11.9
Blood chemistry	Creatinin		0.7~1.3mg/dl	0.8	0.9	1.1	0.9	1.2	1.1	1.2	1.0
em	Na+		134~148mEq/L	140	137	140	138	140	140	139	140
5	K+		3.5~5.0mEq/L	4.0	3.6	4.5	4.4	3.7	3.9	4.2	3.8
po	Cl		98~108mEq/L	104	101	105	102	105	102	100	101
Blo	Coombs(d	lirect)	-	-	_	-		-	-	_	-
	CRP			 	_				_		_
	Albumin		62~72%	70.5	76.2	70.2	72.9	71.0	72.6	73.8	74.6
	α ₁ - globul	in	1.8~3.7%	2.9	2.1	2.8	2.1	3.0	2.3	1.9	1.9
	α2-globul		6.3~10.6%	7.2	6.1	8.5	7.6	6.9	6.6	7.3	7.6
	β- globuli		6.1~10.0%	6.9	6.3	7.2	6.9	7.9	8.0	7.2	6.7
	γ-globuli		9.8~20.5%	12.4	9.3	11.4	10.5	11.1	10.5	9.8	9.1
	IgG		714~1322mg/dl	710.7	715.1	901.5	891.3	631.0	714.6	854.2	843.7
	IgA		87~343mg/dl	302.0	305.2	337.2	333.8	200.5	199.3	227.9	227.8
	IgM		41~190mg/dl	157.6	164.6	219.7	177.2	86.1	93.7	105.3	98.2
	CPK		5~50u/L		36	589			57	81	
	Spec. gra	vity	1.000~1.030	1.021		1.010	1.021	1.010	1.012		1.013
	pН		4.8~7.5	5.0	5.0	7.5	5.0	5.5	5.0	6.5	6.5
	Protein		-~±	1 -	±	_	_	_	_		-
Urinalysis	Glucose		-~±	T -	_	_	_	_		_	
lal ₃	Blood		_	T -	_	_		_	_	_	-
rin	Bilirubin		_	T -	_	_	_	_	_		=
2	Urobilino	gen	0~2.0mg/day	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
		WBC	0~4	0~1	1~2	1~2	1~2	0~1	0~1	0~1	0~1
	Sed.	RBC	0~4	1~2	1~2	1~2	1~2	0~1	0~1	0~1	0~1
	Blood pre		/mmHg			84/138					
	Pulse		/min.	66	84	82	72	68	78	71	76
ers	Respiration	on rate	/min.	17	20	22	16	18	22	20	20
Others	Body tem		°C	36.1	35.9	36.4	35.7	36.4	36.2	36.3	35.8
	ECG		_	_	_	_	_	_		_	
	ESR		1~10/hr	2	4	4	2	1	1	1	2
								<u></u>			

Table 4-2

	13. T.K.					14.	Y.T.			15. `	Y.O.			16. N	M.M.	
	0.8g	1.6g	3.2g		0.8g	1.6g	3.2g		0.8g	1.6g	3.2g		0.8g	1.6g	3.2g	
	Before	Before	Before	1week after	Before	Before	Before	1week after	Before	Before	Before	1week after	Before	Before	Before	1week after
	524	518	514	483	494	481	472	461	511	507	496	511	451	482	467	429
	69 49.5	58 48.5	72 48.5	58 46.0	84 46.0	100 44.0	90 44.5	156 43.5	49 46.0	48 45.5	46 44.5	54 45.5	40.0	64 42.5	52 41.0	55 38.0
	16.9	16.8	16.4	15.8	15.6	15.1	15.0	14.8	16.3	16.1	15.6	16.2	13.0	14.1	13.7	12.5
	25.2	25.5	23.9	19.3	26.3	27.6	26.8	25.9	25.5	25.3	24.2	27.0	31.0	31.6	32.0	33.1
ES	10	7	5	9	10	6	8	9	8	10	8	6	7	5	7 52	9 61
tolo	37	49	56 8	52 5	40	53	58 2	59 3	41	38	37	39	47	53	3	2
Haematology	1	1	2	0	2	0	1	1	1	1	1	0	0	1	1	0
Hae	10	3	2	4	6	4	9	4	7	1	8	8	5	2	5	4
	38	33	27	30	1′00″	37	22	24	42	2'00"	43	45	39	37	32	24
	2′00″ 88	1′ 0″ >100	2'30" >100	1'00" >100	1'00"	1′00″ 92	2'30" 92	2'30" 85	2'00° >100	2'00" >100	2'00"	100	1′00″	2'30" 85	30" 88	1′30″ 85
	31.6"	30.4"	29.4"	30.5"	39.3"	39.0"	40.6"	40.6"	27.0	26.3"	27.3	24.9"	38.4"	35.0"	37.5"	37.6"
	197	205	215	245	253	215	195	185	220	227	290	256	154	205	256	240
	78	76	90	81	84	77	77	72	90	84	90	80	76	76	76	72
	2.67	7.6	7.5 2.75	7.0	7.5 2.58	7.3	7.3	7.1	7.6 2.54	7.6	7.7 2.31	7.7 2.26	3.04	7.8	7.6	2.66
	259	253	254	254	199	182	188	181	212	215	212	230	158	167	165	133
	0.5	0.8	1.3	1.1	0.5	0.8	0.7	0.9	0.7	0.5	0.5	1.0	0.5	0.2	0.4	0.8
	0.2	0.3	0.5	0.4	0.2	0.3	0.3	0.4	0.2	0.2	0.3	0.4	0.2	0.1	0.2	0.2
	0.3	0.5	0.8	0.7	0.3	0.5	0.4	0.6	0.5	0.3	0.2	0.6	0.3	0.1	0.2	0.6
	3 15	3 21	3 14	13	7	9	7	6	14	11	8	5 12	3	9	8	6
	23	29	26	17	6	7	6	4	14	12	13	11	5	5	5	2
, i	9.4	10.1	8.2	8.1	6.7	6.4	5.7	5.8	5.2	5.0	5.1	5.9	6.6	8.6	6.9	8.5
Blood chemistry	16.2	13.9	13.4	13.1	16.0	16.3	15.9	12.8	13.4	12.6	12.1	14.7	16.7	13.9	16.8	17.0
chei	1.2	0.9	1.2	1.0	1.0	1.0	0.8	0.8	1.1	1.0	1.2	1.0	1.2	1.0	1.2	1.0
po	3.7	141	4.1	141	138	138	139	140	140 4.1	140 4.5	4.3	142 4.1	140	141	141	4.7
ΒÌο	108	106	105	104	103	102	104	101	106	103	102	101	106	102	99	102
	_	_	_	_	_	_	_	_	_	_	_	_		_		
	70.7	70.0			+	-	-	-	-	-	-	-	-	-	-	+
	72.7	70.9	73.3	73.7	72.0	71.6	71.1	73.7	71.8	69.1	69.8	2.0	75.3	69.9	69.7	72.7
	7.3	8.8	8.1	8.4	9.5	8.8	8.9	8.7	9.2	7.2	9.0	9.1	7.3	7.6	8.2	8.9
	7.7	7.5	7.2	7.8	7.8	8.5	7.4	6.7	7.2	8.7	7.3	7.9	6.2	7.8	7.8	6.8
	9.6	11.1	9.6	8.2	9.0	9.4	10.8	9.1	10.1	12.6	12.0	11.8	9.5	12.4	12.3	9.4
	590.5 232.4	647.2 225.8	755.5 264.4	729.1	591.3	630.2 203.1	793.8	806.0 242.1	680.0 268.7	713.0	691.8 317.5	1014.4 357.1	636.8 115.9	681.4	919.5	802.3
	139.0	149.2	182.4	165.4	76.1	75.8	104.4	112.4	85.3	80.0	91.0	103.8	76.1	90.8	105.5	133.1 92.8
		39	60			44	48			34	34			45	76	-
	1.024	1.018	1.025	1.021	1.020	1.025	1.020	1.018		1.019	1.015	1.021	1.027	1.029	1.025	1.029
	5.0 ±	5.0	5.5	5.0	5.0	5.0	5.5	6.0	5.0	4.5	5.0	4.5	5.0	5.0	5.0	5.0
sis			_	=	=	=		_		_		_	_	<u>+</u>	_	+
Urinalysis			_	_	_	_	_	_	_	_	_	_	-	-		
Cr.		_	_	_	_	_	_	-	_		_	_		_	_	+
	1.0	1.0	1.0	1.0	1.0	1.0	0.1	1.0	1.0	1.0	0.1	1.0	1.0	1.0	1.0	1.0
	2~3 0~1	1~2 0~1	0~1 0~1	1~2	1~2	2~3 1~2	0~1 2~3	1~2	0~1	2~3	0~1	1~2 2~3	2~3	3~4	1~2	0~1
			84/128					$\frac{1-2}{70/122}$		80/118					2~3 68/114	4~5 72/104
ည	80	66	74	76	68	70	68	76	75	73	72	73	65	70	70	70
Others	20	16	19	17	16	18	18	18	24	19	20	15	18	18	18	16
0	35.7	35.8	35.7	35.5	36.1	36.0	36.0	35.9	36.6	36.0	36.0	36.3	36.2	36.2	36.2	36.2
	2	3	2	2	8	7	4	4	6	7	11	9	7	7	12	17
							_			<u> </u>	11	<u> </u>			14	11

Table 5 Laboratory findings in Series II: BRL 28500 (0.8g, 1.6g, 3.2g, N) bolus)

			e 5 Laboratory findings in Se			K.N.				Г.Т.	
	Ito		Normal range	0.8g	1.6g	3.2g		0.8g	1.6g	3.2g	
	ite	ems	Normal range	Before	Before	Before	1week after	Before	Before	Before	1week after
	RBC		$476 \pm 60 \times 10^4 / \text{mm}^3$	508	515	470	479	476	463	467	470
	WBC		$63 \pm 21 \times 10^{3} / \text{mm}^{3}$	46	51	47	40	58	58	54	62
	Ht		$43.4 \pm 5.3\%$	44.0	44.5	41.0	42.0	43.5	42.0	43.0	44.0
	Hb		$15.7 \pm 2.0 \text{g/dl}$	15.5	15.4	14.2	14.5	15.2	14.6	14.7	14.9
	Platelet		13~35×10 ⁴ /mm ³	23.0	25.2	23.3	22.7	24.2	21.1	34.2	25.0
S		Stab.	$8.3 \pm 6.9\%$	6	7	3	4	3	4	4	2
olo		Seg.	45.1 ± 15.5%	38	31	44	42	50	53	45	55
Haematology	Segmen-	Eosino	$2.7 \pm 4.4\%$	5	3	2	4	3	2	4	11
ıen	tation	Baso.	0.8 ± 1.0%	1	0	0	0	1	0	1	2
Ηε		Mono.	$4.4 \pm 2.7\%$	6	4	1 50	3	5	5	10	5
	701 1'	Lympho.	38.7 ± 14.6%	44	55	50	47	38	36	36	35
	Bleeding	time	1~3min. 70~130%	3'00"	3'30"	2'00"	2'30"	2'00"	1'30"	1′00"	1'00'
	P.T. APTT		$(25^{\circ} \sim 40^{\circ})$	36.1"	85 34.2*	80 35.1"	77 35.9"	74 26.5"	88 25.7"	80 25.9	77
	Fbg		200~400mg/dl	200	205	162	180	186	205	195	395
	Glucose		60~105mg/dl	84	76	78	79	87	83	85	81
i	T.protein		6.6~8.2g/dl	7.7	7.8	7.5	7.4	7.1	7.2	7.1	7.0
	A G ratio		1.4~2.4	2.22	2.17	2.41	2.48	2.43	1.84	2.21	2.43
	T.cholest		150~250mg/dl	152	150	149	147	159	166	168	181
	T.bilirubi		0.1~1.0mg/dl	0.6	0.6	0.6	0.9	0.6	1.2	0.4	0.6
	D.bilirubi		0.1~0.5mg/dl	0.2	0.2	0.3	0.3	0.2	0.8	0.2	0.3
	I.bilirubin			0.4	0.4	0.3	0.6	0.4	0.4	0.2	0.3
	ZTT		3~11u	6	6	6	7	5	6	5	6
	GOT		5~20u/L	13	14	8	10	9	20	6	7
	GPT		2~19u/L	14	9	8	6	6	6	5	6
ry	Al-P		2.7~10K-A	7.2	6.5	5.7	6.0	6.8	13.2	6.7	6.9
Blood chemistry	BUN		7~22mg/dl	16.5	19.8	17.4	14.2	20.2	19.9	16.2	19.2
Jen	Creatinin		0.7~1.3mg/dl	1.3	1.2	1.3	1.1	1.2	1.2	1.2	1.2
	Na+		134~148mEq/L	140	140	141	140	140	139	141	140
000	K ⁺		3.5~5.0mEq/L	3.7	4.3	4.0	3.9	3.6	5.3	3.8	3.9
BI	C1-		98~108mEq/L	106	101	103	102	105	103	107	100
	Coombs(d	lirect)	_					_			
	CRP		_		-			-	_		
	Albumin		62~72%	69.0	68.4	70.7	71.2	70.8	64.8	68.8	70.9
	α₁- globul		1.8~3.7%	1.8	2.1	2.1	1.7	1.8	2.1	2.1	1.6
	C2-globur		6.3~10.6%	7.8	6.5	6.2	7.0	6.9	6.3	5.7	6.9
	β- globuli γ- globuli		6.1~10.0% 9.8~20.5%	6.7	6.9	6.5	6.3	6.4	10.9	7.5 15.9	6.9
	IgG	11	714~1322mg/dl	877.2		1082.4	13.8 960.0	762.8	798.3		
	IgA		87~343mg/dl	242.5	224.1	236.8	253.9	148.0	156.1		
	IgM		41~190mg/dl	160.2	165.8		183.0	32.9	32.2	46.5	46.3
	CPK		5~50u/L	100.2	60	49	100.0	32.3	66	28	10.0
•	Spec. gra	vity	1.000~1.030	1.023	1.025		1.014	1.010			1.012
	рН		4.8~7.5	5.0	6.5	5.5	6.5	5.0	4.5	5.0	4.5
S	Protein		-~±	±	±	±	-	-	-	-	-
Urinalysis	Glucose		-~±	1 -	_	_	_	-	-	-	-
nal	Blood		-		-	_	_	-	-	-	
Uri	Bilirubin		_	_	_	_	_	_	_	_	
	Urobilino		0~2.0mg/day	1.0	1.0	0.1	1.0	1.0	1.0	0.1	0.1
	Sed.	WBC	0~4	0~1	3~4	2~3	1~2	0~1	1~2	0~1	0~1
		RBC	0~4	1~2	1~2	0~1	1~2	0~1	0~1	0~1	0~1
	Blood pre	essure	mmHg	82/124	90/124	78/108	72/114	86/120	86/124		72/118
ý	Pulse		/min	64	67	80	66	66	60	66	66_
Others	Respirati		/min.	17	17	18	17	18	24	18	18
Ö	Body tem	nperature	°C	36.2	36.2	36.3	35.8		35.6	35.9	36.1
	ECG ESR		1~10/hr	12	9	7	5		5	4	7

Table 5-2

		19. 1	K.T.			20. \	Y.M.			21. N	M.M.			22.	K.S.	
	0.8g	1.6g	3.2g		0.8g	1.6g	3.2g		0.8g	1.6g	3.2g		0.8g	1.6g	3.2g	
	Before	Before	Before	1week after	Before	Before	Before	1week after	Before	Before	Before	1week after	Before	Before	Before	1week after
	491	503	471	464	460	459	458	452	499	525	515	478	401	406	402	398
	34 43.0	42	35 41.5	57 41.0	67 44.0	46	56 44.0	52 43.5	69 44.5	69 46.5	66 45.5	67 42.5	79 43.0	99 43.5	70 43.0	74 43.5
	15.0	15.6	14.7	14.5	14.9	14.9	15.0	14.8	15.4	16.2	15.9	15.1	14.5	14.7	14.5	14.5
>	28.0	26.1	27.1	29.7	20.7	22.6	21.1	22.9	25.7	24.8	25.2	22.6	23.5	24.8	25.5	25.2
log	1	3	4	2	9 51	42	47	12 53	6 24	0 45	38	5 41	7 56	64	63	62
natc	54 3	45 1	49	64	3	2	0	1	3	2	6	41	0	0	03	0
Haematology	1	1	0	6	0	2	1	1	3	0	2	1	0	1	0	2
Ξ	2	5	4	24	8	3	5	3	7	3	3	5	6	4	6	5
	3'00"	45 1'00"	40 1'30"	1'30"	29 3'00"	45 3'30"	3'00"	30 1'30"	57 1'00"	50 3'30"	43 2'00"	44 1'30"	31 1'30"	25 2'00"	25 1'30"	23 1′00″
	99	>100	>100	>100	68	>100	>100	>100	68	61	74	64	80	92	85	74
	27.2	25.1"	26.2"	25.6"	37.6"	28.4"	26.7"	26.9"	37.6"	37.2"	36.7"	36.2"	35.8	31.9"	32.2"	32.4"
	176	242	215	273	178	215	207	196	178	195	227	195	160	242	230	193
	7.5	84	7.6	7.5	83 7.6	87 7.8	7.9	75 7.5	76 7.6	78	76	76 7.1	79 6.8	79	72	6.8
	2.52	0.0	2.33	1.5	3.03	2.54	2.62	2.64	2.02	1.85	1.83	2.01	3.43	3.20	3.06	3.26
	183	199	183	174	135	157	168	147	154	153	153	141	125	154	141	141
	0.6	0.9	0.5	0.4	1.2	1.0	0.8	1.2	0.5	0.5	0.5	0.5	0.6	0.5	0.6	0.8
	0.2	0.3	0.3	0.2	0.5	0.4	0.3	0.5	0.2	0.3	0.3	0.3	0.2	0.3	0.3	0.4
	6	6	7	6	4	4	5	5	8	8	9	8	4	4	4	4
	21	22	16	16	13	12	13	17	11	12	9	8	15	15	12	11
	24	27	26	14	13	11	16	14	8	8	9	6	6	7	6	4
	12.1	13.9	3.9	12.5	3.5 25.2	3.7	3.9	3.9	7.9	8.2 13.1	7.6	7.4	9.0	8.7 13.0	7.9	8.1
	1.0	0.9	1.0	0.9	1.3	1.3	1.3	1.1	1.0	0.9	1.0	0.9	1.0	0.9	1.1	1.1
	139	137	138	138	141	139	140	141	141	141	141	141	140	140	141	141
Ϋ́	3.8	4.5	4.0	3.9	3.7	4.0	4.1	3.7	3.8	3.8	4.2	4.0	3.8	4.6	3.9	4.1
Blood chemistry	105	101	102	103	105	103	102	102	107	105	102	103	107	103	105	103
che	_	_	_		_					_	_	_	_			
ğ	71.6	68.3	69.9	69.9	75.2	71.8	72.3	72.6	66.9	64.9	64.7	66.7	77.4	76.2	75.4	76.5
Blo	1.9	2.1	2.3	2.0	1.5	1.7	2.4	1.6	2.0	2.3	2.1	1.7	1.8	2.1	2.7	2.4
	6.3	7.1	6.3	8.7 6.8	6.3	6.4 8.5	5.8 7.9	7.7	6.9	6.3	7.0	7.8 6.6	6.9 5.2	6.1	6.0	7.0 5.9
	12.5	14.9	14.0	12.6	10.3	11.5	11.5	10.7	17.9	19.6	19.7	17.1	8.7	9.3	9.8	8.1
	864.7	745.9	1035.1	1045.2	754.0	737.1	951.1	900.9	1127.0			1314.7	619.5	558.8	741.7	612.6
	152.3 78.3	151.7 87.8	173.3	184.1	294.7	279.3	339.6	341.6	209.4	177.3	255.5	212.2	76.9	72.7	95.1	90.3
	10.3	63	92.0	97.0	82.0	93.7	108.1	104.3	163.5	189.7 27	225.6 45	187.5	43.2	45.0 73	55.4 69	55.2
	1.020	1.019	1.020	1.019	1.027	1.019	1.010	1.016	1.027	1.029	1.030	1.018	1.020	1.014	1.015	1.020
	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.5	5.5	5.0	5.0	5.0	5.5	5.5	5.0
ysis		_	_							_		_				
Urinalysis	_		=		_		_							_	=	
'n		_	_	_	_	_	_	_		_	_	_	_		_	_
	1.0	1.0	0.1	1.0	1.0	1.0	0.1	1.0	1.0	1.0	0.1	1.0	0.1	1.0	0.1	1.0
	0~1 0~1	2~3	1~2	0~1	0~1	1~2	0~1	1~2	3~4	5~9	0~1	2~3	0~1	1~2	0~1	0~1
		1~2 92/118	0~1 78/102	0~1 86/128	0~1 88/130	0~1 86/124	0~1 80/124	1~2 80/132	74/108	74/106	0~1 70/108	0~1 72/116	0~1 84/116	1~2	0~1 78/116	0~1 80/126
v	75	90	78	90	78	83	86	82	72	70	72	66	72	72	73	72
Others	17	18	20	24	20	19	20	19	19	18	18	18	18	18	18	17
ō	36.0	36.0	36.1	36.1	35.4	35.3	35.8	36.0	36.1	36.4	35.9	35.8	36.1	36.2	36.3	36.3
	8		7	12	5	6	5	9	8	6	7	6		2	7	5
		<u> </u>		خد	3	9	J	3	<u> </u>		·					

Table 6 Laboratory findings in SeriesIII: BRL 28500 3.2g, TIPC 3.0g, CVA 0.2g ($\mathbb N$ bolus)

					23.	Y.K.			24. :	S.K.	
	1	tems	Normal range	TIPC	BRL	CVA		TIPC	BRL	CVA	
	1	tems	Normal range	Before	Before	Before	lweek after	Before	Before	Before	l week after
	RBC		$476 \pm 60 \times 10^4 / \text{mm}^3$	500	501	491	487	523	502	502	500
	WBC		$63 \pm 21 \times 10^{3} / \text{mm}^{3}$	47	41	42	49	39	37	34	37
	Ht		$43.4 \pm 5.3\%$	43.5	44.0	43.0	42.9	47.5	45.5	45.5	44.5
	Hb		$15.7 \pm 2.0 \text{g/dl}$	15.5	15.5	15.0	15.1	16.3	15.6	15.6	15.7
	Platelet		$13\sim35\times10^{4}/\text{mm}^{3}$	18.8	19.5	18.5	18.2	21.7	17.9	19.0	20.8
33		Stab.	$8.3 \pm 6.9\%$	9	0	5	3	6	4	11	7
olog		Seg.	$45.1 \pm 15.5\%$	33	46	38	29	38	44	44	35
Haematology	Segmen-	Eosino.	$2.7 \pm 4.4\%$	1	2	1	3	1	1	3	2
em	tation	Baso.	$0.8 \pm 1.0\%$	0	2	1	1	0	0	0	0
На		Mono.	$4.4 \pm 2.7\%$	3	5	3	0	3	9	4	3
		Lympho.	$38.7 \pm 14.6\%$	54	45	52	64	52	42	38	53
	Bleeding	time	1~3min.	3′00″	3'30"	3'00"	5′30″	2'30"	2'00"	1′00*	2'30"
	P.T.		70~130%	88	80	88	80	77	66	66	70
	APTT		(25"~40")	29.8"	29.9"	29.6"	28.4"	32.5"	32.9"	34.3"	30.7
	Fbg		200~400mg/dl	185	178	170	162	170	195	169	178
	Glucose		60~105mg/dl	74	72	87	81	64	73	73	69
	T.protein		6.6~8.2g/dl	8.2	8.1	8.1	8.3	7.6	7.3	7.2	7.6
	A/G ratio)	1.4~2.4	2.26	2.32	2.35	2.41	3.03	3.05	3.31	3.18
	T.choleste	erol	150~250mg/dl	186	184	187	197	158	150	144	160
	T.bilirubi	n	0.1~1.0mg/dl	0.7	0.8	0.5	0.9	0.5	0.8	0.6	1.0
	D.bilirubii	ı	0.1~0.5mg/dl	0.2	0.3	0.1	0.3	0.1	0.2	0.2	0.4
	I.bilirubin			0.5	0.5	0.4	0.6	0.4	0.6	0.4	0.6
	ZTT		3~11u	10	11	10	11	5	5	5	6
	GOT		5~20u/L	7	13	12	11	8	12	13	12
	GPT		2~19u/L	4	13	5	8	1	7	5	2
Ę	Al-P		2.7~10K-A	3.9	4.1	4.0	3.8	4.3	3.8	3.7	3.7
Blood chemistry	BUN		7~22mg/dl	17.0	14.6	14.0	11.7	14.2	14.8	13.4	13.6
her	Creatinin		$0.7 \sim 1.3 \text{mg/dl}$	1.1	1.1	1.1	1.0	0.9	1.1	1.2	1.1
	Na+		134~148mEq/L	138	137	140	139	140	140	141	141
000	K+		3.5~5.0 mEq/L	3.9	3.9	4.0	3.8	4.0	3.5	3.6	4.1
Bl	Cl-		98~108mEq/L	101	100	103	101	101	102	103	103
	Coombs(d	irect)			_		_	_	_	_	
	CRP				_		_	_	_		
	Albumin		62~72%	69.4	69.9	70.2	70.7	75.2	75.3	77.8	76.0
	α_{i-g} lobul		1.8~3.7%	2.1	1.6	2.0	1.7	2.4	1.8	1.9	1.8
	α_2 -globul		6.3~10.6%	5.1	5.0	5.5	5.1	5.2	5.4	5.9	5.3
	β-globuli		6.1~10.0%	6.0	6.1	5.9	5.8	5.8	5.9	5.4	6.1
	γ-globuli	n	9.8~20.5%	17.5	17.4	16.5	16.7	11.4	11.5	10.0	10.8
	IgG		714~1322mg/dl			1310.2			931.6	902.6	
	IgA	****	87~343mg/dl	110.8		113.8				131.2	
	IgM		41~190mg/dl	59.4	58.0	63.4	57.4	70.5	66.7	77.0	68.8
	Spec. grav	rity	1.000~1.030			1.020			1.020	1.027	
	pН		4.8~7.5	5.0		5.0			5.0	5.0	6.5
.v	Protein		-~ ±				_		±		
lysi	Glucose		-~±					_		_	
Urinalysis	Blood		_		_			_			
U	Bilirubin		_								-
	Urobiling		0~2.0mg/day	1.0	1.0	1.0	0.1	1.0	0.1	1.0	0.1
	Sed.	WBC	0~4	0~1	0~1	1~2	1~2	0~1	0~1	0~1	
		RBC	0~4	1~2	0~1	0~1	0~1	0~1	0~1	0~1	1~2
	Blood pre	essure	mmHg			84/120					
Š	Pulse		/min.	64	70	68	68	60	60	56	60_
Others	Respiration		/min.	17	14	14	14	18	18	16	18
Õ	Body tem	perature	C	36.2	36.7	36.3	36.6	36.5	36.7	36.4	36.5
	ECG			-	<u> </u>						-
	ESR(1hr)		1~10/hr	8	5	5	5	16	2	2	2

Table 6-2

		25. I	ζ.H.			26. I	К.Т.			27.	Y.A.			28. I	M.N.	
	TIPC	BRL	CVA		TIPC	BRL	CVA		CVA	TIPC	BRL		CVA	TIPC	BRL	
	Before	Before	Before	1week after	Before	Before	Before	1week after	Before	Before	Before	1week after	Before	Before	Before	lweek after
	458	469	465	465	515	510	505	490	499	481	502	479	465	416	427	397
	50	56	48	46	57 45.0	52 44.5	56 43.5	48	46 42.5	40	47 42.5	47	45.5	45 41.5	37 42.5	37
	44.5 15.5	45.0 15.9	44.5 15.6	44.5 15:5	15.7	15.7	16.0	14.8	15.2	14.9	15.2	14.6	16.5	14.7	15.1	14.2
	19.1	19.8	19.6	19.7	22.4	23.4	22.3	23.1	34.3	34.3	32.9	31.9	24.7	24.0	23.3	22.8
>	5	9	3	5	1	1	3	3	13	7	5	6	5	7	7	2
log	57	56	51	46	60	53	53	51	45	49	45	36	35	44	43	54
Haematology	5	3	4	1	2	2	1	0 2	0	4	0	0	0	5	3	0
aem	4	4	8	6	2	4	3	5	5	3	1	6	7	3	3	6
Ħ	27	26	34	42	35	39	39	39	36	36	45	48	51	39	43	36
	1'00"	2'00"	2'30"	2'30"	2'00"	2'30"	4'30"	3′00″	1′30″	2'00"	4'00"	1′30″	1′00″	3′30″	2'00"	2'30"
	77	70	74	70	80 00 C"	80	85	77	61	63	68	63	92	>100	100	92
	37.1° 205	39.1"	37.1"	36.8"	29.6" 156	31.5" 137	28.3" 169	29.7"	39.1"	39.2" 169	37.2" 195	37.9°	34.7"	38.3° 195	35.3" 185	35.2" 185
	78	76	86	77	82	79	87	84	67	68	78	75	87	70	82	79
	7.8	7.4	7.8	7.9	7.9	7.8	8.2	7.8	8.2	7.5	7.7	7.7	8.6	7.1	7.3	7.3
	2.69	2.95	3.12	3.04	2.61	2.68	2.54	2.79	2.95	3.19	2.94	3.05	2.52	2.85	2.65	2.88
	181 0.7	0.5	169	0.8	0.8	0.8	0.5	0.8	0.9	0.5	0.8	144	0.8	0.6	163 0.8	156 0.8
	0.7	0.5	0.2	0.8	0.8	0.3	0.5	0.8	0.9	0.5	0.8	0.3	0.8	0.0	0.8	0.8
	0.5	0.4	0.8	0.5	0.6	0.5	0.3	0.5	0.6	0.4	0.6	0.7	0.6	0.4	0.5	0.6
	5	5	5	6	8	7	6	7	6	5	5	5	8	6	6	7
	5	9	8	6	9	14	13	11	11	13	16	14	14	12	15	12
	5.9	5.9	5 6.4	5.7	5 8.8	12 12	9.6	8.7	6.8	15 8.4	12 6.4	6.5	6.7	6.7	6.1	6.3
try	10.5	14.1	10.1	10.5	16.6	15.3	17.2	13.0	13.7	11.6	13.9	14.6	12.9	14.4	14.7	11.0
mis	1.0	1.0	1.1	1.0	1.0	1.1	1.1	1.1	1.1	1.2	1.2	1.0	1.1	1.1	1.2	1.0
che	139	139	141	140	138	138	140	137	138	138	139	138	138	139	139	137
Elood chemistry	3.5	3.9	3.7	3.8	3.7	4.5	3.9	4.0	4.1	3.9	4.2	4.1	4.4	4.2	4.7	3.9
120	100	102	103	103	102	102	105	102	102	101	103	102	101	102	103	103
	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	
	72.9	74.7	75.7	75.2	72.3	72.9	71.8	73.6	74.7	76.1	74.6	75.3	71.6	74.0	72.6	74.3
	2.7	1.8	2.1	1.8	2.1	1.2	1.9	1.4	2.2	1.4	2.1	1.7	2.2	1.4	1.8	1.6
	6.2	6.2 5.7	6.1 5.5	5.8	5.9 6.0	7.1 5.7	7.2 6.3	5.9	5.8	5.8 6.1	6.7	6.2	5.5 6.4	5.8 6.1	6.8	5.8 6.5
	12.0.	11.7	10.5	11.4	13.6	13.1	12.9	13.1	11.0	10.6	10.3	10.2	14.3	12.6	6.1	11.8
	967.6	764.5	841.3	1059.2		1238.4	1091.6		863.4	966.8	914.1	907.4	1136.0		985.3	1008.3
	112.7	118.0	136.0	110.3	178.2	178.9	209.4	184.8	52.9	94.7	72.9	61.2	179.8	155.7	180.5	145.9
	86.3	83.2	1.025	83.3	84.6	82.0	89.6	76.1	226.7	225.0	225.9		80.7	75.9	78.5	66.9
	5.5	5.5	5.5	5.5	5.0	5.0	1.026 4.5	1.020 5.0	4.5	5.0	5.0	1.027 5.0	7.5	5.5	1.017 6.0	1.010 5.5
rn .	-	_	-	-	-	-	4.3	-	4.5	3.0	3.0	J.U	1.5	-	0.0	-
lysis	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	
Urinalysis				±	_		_			_	_			_		
ņ	1.0	1.0	0.1	0.1	1.0	-	-	-	-	-	-	-	-	-	-	
	1~2	0~1	$\frac{0.1}{0 \sim 1}$	1~2	1.0	0.1	0.1	0.1	2~3	0.1 5~9	1.0 3~4	0.1	1.0	0.1 2~3	0~1	$\frac{0.1}{0 \sim 1}$
	0~1	2~3	0~1	0~1	0~1	0~1	0~1	1~2	0~1	2~3	0~1	1~2	0~1	2~3	0~1	0~1
		84/110					88/128	76/110		76/118		74/122	78/136			76/112
ers	68	80	80	84	72	80	80	74	60	60	66	64	72	70	68	72
Others	36.1	36.5	16 35.8	16 36.4	36.2	18 36.3	20 36.7	22 36.7	18 35.6	16 35.7	18	25.9	20	18	16	12
	_	-	-	-	-	-	-	30.7	-	35.7	35.4	35.8	36.7	36.3	36.2	36.2
	4	2	2	1	5	3	3	3	8	3	3	4	4	2	2	2

Table 7 Laboratory findings in SeriesIII: BRL28500 3.2g, TIPC 3.0g, CVA 0.2g (Nbolus)

					29. 1	N.A.			30. 9	S.M.	_
				CVA	TIPC	BRL		CVA	TIPC	BRL	
	It	ems	Normal range	CVA	TIFC	DKL		CVA	TIFC	DKL	
			Norman range	Before	Before	Before	1week after	Before	Before	Before	1week after
	RBC		$476 \pm 60 \times 10^4 / \text{mm}^3$	496	481	470	468	488	481	479	458
Ì	WBC		$63 \pm 21 \times 10^{3} / \text{mm}^{3}$	64	60	63	64	66	78	69	77
	Ht		43.4 ± 5.3%	44.5	44.0	42.5	42.0	46.5	46.5	45.0	43.5
	НЬ		$15.7 \pm 2.0 \text{g/dl}$	15.7	15.4	15.1	15.1	16.1	15.9	16.5	15.2
	Platelet		13~35×10 ⁴ /mm ³	28.7	26.4	26.9	27.9	26.9	28.9	26.8	26.6
2		Stab.	8.3 ± 6.9%	3	9	1	2	6	8	11	6
- SG		Seg.	45.1 ± 15.5%	67	52	62	43	48	51	38	57
ato	Segmen-	Eosino.	$2.7 \pm 4.4\%$	1	1	1	3	1	1	3	2
Haematology	tation	Baso.	0.8 ± 1.0%	0	2	3	1	0	0	0	1
Ha	tution	Mono.	4.4 ± 2.7%	3	3	3	4	9	9	7	3
		Lympho.	38.7 ± 14.6%	26	33	30	47	36	31	41	31
	Bleeding		1~3min	2'30"	3'00"	4'00"	3'30"	1'30"	3'30"	2'00"	2'30'
	P.T.		70~130%	88	>100	92	80	>100	>100	>100	>100
	APTT		(25"~40")	34.3"	37.9"	36.9"	36.9"	30.7"	32.0	30.6"	29.8
	Fbg		200~400mg/dl	290	256	242	256	227	227	215	256
	Glucose		60~105mg/dl	88	80	94	87	79	77	83	76
	T.protein		6.6~8.2g/dl	8.3	7.7	8.0	7.9	7.8	7.6	7.6	7.6
	A/G ratio		1.4~2.4	2.18	2.57	2.56	2.52	2.11	2.31	2.47	2.28
	T.cholest		150~250mg/dl	256	238	257	259	224	216	234	228
	T.bilirubi		0.1~1.0mg/dl	1.0	0.6	0.7	1.0	0.8	0.4	0.7	0.5
	D.bilirubi		0.1~0.5mg/dl	0.3	0.2	0.2	0.4	0.2	0.2	0.1	0.2
	I.bilirubin			0.7	0.4	0.5	0.6	0.6	0.2	0.6	0.3
	ZTT		3~11u	4	6	6	6	4	4	3	4
	GOT		5~20u/L	12	17	20	14	10	12	12	13
>	GPT		2~19u/L	13	24	23	20	10	16	13	12
Blood chemistry	Al-P		2.7~10K-A	5.9	5.9	5.8	5.7	7.5	8.6	7.7	7.8
Ē	BUN		7~22mg/dl	19.6	16.6	19.1	19.3	14.7	14.9	17.4	14.9
che	Creatinin		0.7~1.3mg/dl	1.0	1.1	1.0	1.2	1.1	1.3	1.1	1.2
Þ	Na+		134~148mEq/L	140	140	141	141	138	139	140	138
100	K+		3.5~5.0mEq/L	3.8	4.1	4.1	3.9	4.4	4.2	4.2	4.2
ង	Cl-		98~108mEq/L	103	103	105	102	101	102	103	102
	Coombs(d	lirect)	_		_	-	_	-	_	_	_
	CRP		-	+	_	_	_	_	_		_
	Albumin		62~72%	68.6	72.0	71.9	71.6	67.8	69.7	71.1	69.5
	α₁-globul	in	1.8~3.7%	2.4	1.7	1.9	1.8	2.6	1.8	2.1	2.0
	α2-globul		6.3~10.6%	6.9	7.1	7.8	7.4	9.5	10.2	9.1	9.8
	β- globuli		6.1~10.0%	7.9	7.4	6.9	8.0	7.1	7.0	7.4	7.5
	γ- globuli		9.8~20.5%	14.2	11.9	11.5	11.2	13.0	11.3	10.3	11.2
	IgG	-,	714~1,322mg/dl	1,094.6	975.9	1,058.4	1,028.5	684.8	868.3	922.7	921.9
	IgA		87~343mg/dl	307.3	246.0	306.8	258.8	351.2	320.3	350.3	308.9
	IgM		41~190mg/dl	114.7	103.1	123.6		76.4	74.4	77.6	65.1
	Spec. gra	vity	1.000~1.030	1.027	1.030		1.025	1.008	1.010		1.005
	pН		4.8~7.5	4.5	5.0	5.0	5.0	6.0	6.0	6.0	6.0
	Protein		1-~±	+	±	±	+		_	±	
Urinalysis	Glucose		- ~ ±	T -	_	_	_		-		
ıaly	Blood		_		_	_	_		_	_	±
li.	Bilirubin		-	_	_	_	_	_	_		
D	Urobilino	gen	0~2.0mg/day	1.0	1.0	1.0	0.1	0.1	0.1	0.1	0.1
	Sed.	WBC	0~4	5~9	1~2	0~1	1~2	2~3	0~1	0~1	1~2
	ocu.	RBC	0~4	1~2	0~1	0~1	1~2	0~1	0~1	0~1	0~1
	Blood pre		mmHg	88/126	94/128	94/122	78/115	78/116	80/114	78/110	72/108
	Pulse		/min.	72	57	62	62	72	71	68	70
ers	Respirati	on rate	/min.	16	17	20	18	16	16	17	16
Others	Body ten	perature	C	36.4	36.1	36.2	36.2	36.2	35.8	35.7	36.5
\mathcal{O}	ECG		_	_	_	_	_	_	-		
	ESR(1hr)	1~10/hr.	15	9	7	10	14	13	11	16
					•			·			

Table7-2

		31.	Y.K.			32.	Y.T.			33.	H.I.			34. 1	N.H.	
	BRL	CVA	TIPC		BRL	CVA	TIPC		BRL	CVA	TIPC		BRL	CVA	TIPC	
	Before	Before	Before	1week after	Before	Before	Before	1week after	Before	Before	Before	1week after	Before	Before	Before	1week after
	527	517	521	501	512	485	504	485	483	487	490	472	505	476	485	489
	38	36	32	31	51	48	55	45	54	54	63	56	60	60	66	53
	48.0	47.0	47.0	45.5	49.5	46.5	48.5	46.0 16.1	45.5 15.4	46.5 15.6	46.0 15.7	44.5 15.3	47.5	44.5 15.7	45.0 16.3	45.0 16.3
	16.4	16.0	16.1 23.0	15.6 26.8	17.3	16.4	16.8 15.1	14.5	23.5	23.5	24.9	23.7	18.1	19.8	19.5	21.7
۶	25.4 5	23.6	14	3	6	8	12	4	5	9	2	4	9	15.8	10	4
Haematology	50	53	51	54	56	51	47	56	52	48	53	58	55	52	50	40
ato	2	2	1	1	0	2	0	1	1	0	2	3	2	2	2	7
eш	1	0	0	3	1	2	3	3	1	0	2	2	0	0	0	2
Ha	6	4	9	6	1	9	7	4	3	7	3	5	6	4	7	4
	36	35	25	33	36	28	31	32	38.0	36.0	38.0	28.0	28	27	31	43
	1′30°	2'30"	1'30"	3′30″	3'00"	1′00″	1'30"	2'30"	1′30″	5'30"	2'00"	4'00"	1'30"	1'00"	1'00"	2'00
	>100	>100	99	85	100	99	100	92	74	74	64	66	99	85	80	64
	24.8"	25.9"	25.8"	24.5"	31.8"	33.5"	32.2"	31.8"	30.8"	32.4"	30.6	32.4	30.2"	31.7	29.9"	29.4"
	178	195	150	156	215	205	185	242	195	242	178	150	169	150	145	162
	82	77	81	81	87	79	93	7.5	70	7.6	75 7. c	61 7.6	7.6	79	93	88 7.7
	2.50	7.8	7.9	7.9	2.39	2.52	7.5	2.46	7.9	2.17	7.6	2.28	2.95	6.8	3.44	$\frac{7.7}{2.76}$
	258	263	240	258	265	236	267	271	157	157	169	169	198	183	186	219
	0.8	0.8	0.9	0.8	0.8	0.6	0.7	0.7	0.9	0.6	0.6	0.9	0.6	0.5	0.4	0.9
	0.2	0.2	0.2	0.2	0.3	0.1	0.2	0.3	0.2	0.1	0.2	0.4	0.2	0.2	0.1	0.4
	0.6	0.6	0.7	0.6	0.5	0.5	0.5	0.4	0.7	0.5	0.4	0.5	0.4	0.3	0.3	0.5
	7	4	4	4	2	4	4	5	7	7	7	8	2	3	3	3
	17	29	21	18	4	14	12	12	8	12	11	11	14	14	22	18
	12	31	20	20	8	15	11	9	2	8	5	3	10	18	25	20
try	7.2	6.8	6.4	6.6	8.8	9.4	9.0	9.0	10.0	10.7	10.6	10.3	6.4	6.1	6.9	7.3
mis	18.4	14.8	12.8	16.0	17.9	13.7	13.9	15.6	13.7	13.9	15.4	15.3	12.3	11.7	12.0	12.5
he	1.0	1.2	1.3	1.2	1.0	1.2	1.1	1.2	0.9	1.1	1.0	1.1	0.9	0.9	1.0	1.0
þ	140	139	141	140	139	139	141	140	137	139	140	138	138	138	140	141
Blood chemistry	101	4.1	104	101	100	3.9	5.2	102	97	100	102	99	3.8	3.8	102	3.8
щ	101	101	104	101	100	99	_	102	91	100	102	99	99	102	102	101
		_	_					_	+				-	_	-	
	71.4	74.0	74.4	73.0	70.5	71.6	70.7	71.1	68.6	68.4	69.5	69.5	74.7	75.9	77.5	73.4
	2.7	1.5	2.4	1.8	1.3	1.6	1.4	1.2	2.7	2.0	1.7	1.7	2.4	1.4	1.2	1.8
	7.7	7.9	8.1	8.0	8.2	7.5	8.0	7.8	6.8	7.6	7.2	6.8	7.2	7.3	7.2	8.1
	7.8	7.6	7.6	7.4	7.9	7.8	7.7	8.1	7.9	8.3	8.1	8.6	7.3	7.1	6.3	7.5
	10.4	8.9	7.5	9.8	12.2	11.5	12.1	11.8	13.9	13.7	13.5	13.4	8.4	8.3	7.8	9.1
	863.1	834.0	850.8	824.2	627.6	800.0	489.8	912.5			1.121.3		816.5	668.3	733.4	753.1
	230.1	179.5	194.7	174.6	359.4	287.8	339.5	272.2	361.5		353.7	302.4	130.9	122.0	144.6	127.0
	70.3	52.2	67.2	57.8	117.1	103.0	116.5	103.8	89.1	72.2	93.1	81.9	41.1	35.8	41.6	40.7
	1.026 4.5	1.020 5.5	1.018 5.0												1.014	
	7.0	-	5.0	5.5	4.5 ±	7.0	5.0	6.0	6.5	5.5	5.0	5.5	5.0	5.5	5.0	5.5
sis				_		_					-		 -	-	-	
Urinalysis	_		_		_	-						_	-	-		
Jrir	-	_	_	_	_			_				_		 _ _	 	
ב	1.0	0.1	1.0	0.1	1.0	0.1	1.0	0.1	0.1	0.1	1.0	1.0	1.0	0.1	0.1	0.1
	0~1	0~1	0~1	2~3	1~2	0~1	0~1	0~1	0~1	1) ~ 1	0~1	2~3	0~1	0~1	0~1	2~3
	0~1	0~1	0~1	0~1	2~3	0~1	0~1	0~1	0~1	0~1	0~1	1~2	0~1	0~1	0~1	1~2
			102/140							86/124	88/108	74/114	92/134	106/138	88/136	80/128
LS	72	75	78	72	64	64	68	64	60	60	60	60	72	72	60	66
Others	18 36.2	18	18	18	20.	20	16	18	12	12	12	12	18	15	11	15
0	30.2	36.2	36.3	36.5	36.4	36.2	36.2	36.6	36.2	36.2	35.3	36.2	35.6	36.1	36.2	36.3
	17	2	3	2	5	5	2		11	-	-		-		-	
	11		<u>ა</u>		1 3	<u> </u>	L	5	11	9	8	5	2	2	2	5

因に関する検査, 心電図検査などを実施し, 皮内反応陰 性および健常人であることを確認した。

検討期間は昭和 58 年4月より7月の4ヵ月間であった。

2. 試験概要

試験の概要は Table 1 に示すシリーズ 1, 2 および 3 の 3 シリーズで行い、ヒトにおける安全性を検討した。 同時に、シリーズ 1 では筋肉内投与時の吸収・排泄、シリーズ 2 では静注時における 投与量の 増減による dose response、そしてシリーズ 3 では TIPC と CVA の薬剤 相互作用について検討した。

3. 投与薬剤および投与方法

BRL 28500 0.8g [CVA-K 0.05g (力価)+TIPC 0.75g (力価)], 1.6g [CVA-K 0.1g (力価)+TIPC 1.5g(力価)], 3.2g[CVA-K 0.2g(力価)+TIPC 3.0g (力価)], TIPC 3.0 (力価)および CVA-K 0.2g (力

価)を使用した。

シリーズ 1 では BRL 28500 0.8 g を 2 ml の 0.5% リドカインに溶解し、筋肉内投与した。シリーズ 2 では 1 週間の間隔を置いて、BRL 28500 0.8 g, 1.6 g および 3.2 g を 10 ml の注射用蒸留水に溶解して 3 分間で順次 静脈内投与した。シリーズ 3 では投与間隔 1 週間の cross over 法で BRL 28500 3.2 g, TIPC 3.0 g および CVA-K 0.2 g を 20 ml の注射用蒸留水に溶解し、 3 分間で静脈 内投与した。

4. 摂食·摂水条件

投与の 12 時間前から 絶食と し、 投与 2 時間後に約 250 ml の水分 (ジュース) を補給し、食事の制限は4時間目の採血・採尿後に解いた。

5. 臨床検查項目

試験中に実施した臨床検査項目を Table 2 に示した。 被試者に対して原則として、投与1週間前、直前およ

Table 8 Serum concentration in Series I: BRL28500 (0.8g, IM)

No.	Time(hr.) Drug	1/6	1/3	1/2	3/4	1	5/4	3/2	2	4	6
-	TIPC	11.36	17.98	21.61	23.76	27.53	23.90	21.22	19.73	7.71	2.42
1	CVA	0.77	1.23	1.23	1.21	1.21	0.99	0.92	0.90	0.28	<0.08
	TIPC	26.63	32.27	31.88	30.18	28.23	28.04	22.03	16.64	3.99	< 0.78
2	CVA	1.87	1.99	1.76	1.57	1.38	1.15	1.04	0.80	0.20	< 0.08
3	TIPC	3.16	6.63	8.96	11.31	16.35	17.07	14.41	14.88	7.46	2.28
3	CVA	0.24	0.36	0.44	0.55	0.71	0.75	0.72	0.66	0.24	< 0.08
	TIPC	16.96	22.83	26.53	26.60	30.20	27.00	22.30	17.87	5.77	1.65
4	CVA	1.17	1.50	1.50	1.44	1.33	1.07	0.98	0.76	0.20	< 0.08
5	TIPC	1.87	4.35	6.90	10.37	15.33	17.21	16.24	14.70	8.87	3.38
5	CVA	0.11	0.26	0.43	0.62	0.82	0.86	0.90	0.76	0.38	0.09
6	TIPC	25.01	30.41	33.85	33.08	30.74	25.89	20.06	14.64	3.17	< 0.78
О	CVA	1.70	1.89	1.95	1.76	1.45	1.10	1.00	0.79	0.18	<0.08
7	TIPC	12.85	16.47	21.00	22.83	24.02	22.91	20.32	17.94	7.04	2.12
1	CVA	0.84	1.16	1.26	1.27	1.22	1.13	0.99	0.90	0.35	<0.08
8	TIPC	14.19	19.53	22.05	19.95	23.42	19.96	17.69	14.16	5.40	1.61
0	CVA	1.08	1.45	1.40	1.40	1.20	1.01	0.91	0.80	0.24	<0.08
	TIPC	3.30	6.42	9.40	12.84	15.16	15.17	16.10	16.24	9.30	4.15
9	CVA	0.24	0.41	0.58	0.66	0.72	0.76	0.88	0.78	0.38	0.09
10	TIPC	3.44	6.78	9.53	16.43	21.02	22.25	21.93	20.66	10.91	3.66
10	CVA	0.23	0.38	0.52	0.75	0.85	0.99	1.06	0.99	0.38	0.09
TIDO	Mean	11.88	16.37	19.17	20.73	23.20	21.94	19.23	16.75	6.96	2.20
TIPC	±S.D.	9.09	10.19	9.96	7.94	6.04	4.46	2.88	2.26	2.42	_
CVA	Mean	0.82	1.06	1.11	1.12	1.09	0.98	0.94	0.81	0.28	<0.08
	±S.D.	0.63	0.66	0.57	0.44	0.28	0.15	0.10	0.09	0.08	

Ξ
=
.8g.
w.
.0
Ξ
8
Ñ
8
BRL 28500
2
M
• •
_
7
ق
erie
Seri
ם.
Ĕ
-5
ā
÷
oncentra
ర
Ĕ
೮
_
-
ĕ
Urin
5
_
6
<u>•</u>
ble

No.	Time (hr.)	0-2	2	2-4	4	4-	4-6	8-9	8	8-0	8
\dashv	Item	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA
	Concentration $(\mu g/ml)$ Urine volume (ml)	1,972.20	92.90	1,581.40	47.50	541.40	12.70	112.50	2.70	187	185 00
	Excretion (mg)	246.53	11.61	197.68		62.26		13.50	0.32	519.96	
	Excretion rate (%)	32.87	23.23	26.36	11.88	8.30	2.92	1.80	0.65	69.33	38.67
	Concentration ($\alpha g/ml$) Urine volume (ml)	2,811.20	124.10	893.20	30.30	364.20	12.80	80.70	2.90	515	-15 00
	Excretion (mg)	337.34	14.89	147.38		36.42		10.49		531.63	21.55
	Excretion rate(%)	44.98	29.78	19.65	10.00	4.86	2.56	1.40	0.75	70.88	43.10
	Concentration (ug/ml)	2,375.80	119.60	3,048.20	104.70	1,376.60	37.60	232.60	5.40		
	2	20.08		.67	75.00	0,	70.00	00.511		34(340.00
***************************************	Excretion (mg) Excretion rate (%)	190.06	9.57	30.48	7.85	96.36	2.63	26.75	0.62	541.79	20.67
	Concentration (µg/ml)	1,590.90	70.10	1,572.00	47.10	324.80	9.30	62.70	1.90	£7:71	11.00
	Urine volume (ml)	190.00		120.00	00	185.00	00.	235.00	00:	73(730.00
	Excretion (mg)	302.27	13.32	188.64	5.65	60.09	1.72	14.73	0.45	565.73	21.14
	Excretion rate (%)	40.30	26.64	25.15	11.30	8.01	3.44	1.96	0.89	75.43	42.28
		1,423.60	09.77	1,878.20	06.79	747.80	23.60	249.70	8.80		
2	i i	120.00		120.00		140.00		130.00		510	510.00
	Excretion (mg) Excretion rate (%)	170.83	9.31 18.63	225.38	8.15	104.69	3.30	32.46	1.14	523.37	21.91
+	Consentantion (a/ml)	26.10	10.02	00.00	10.30	13.30	10.01	4.33	27.73	11.16	49.06
	Urine volume (ml)	65.00	N	1,912.60 70.00	06.79	352.10 85	1 12.70 85.00	123.20	70.00 5.20	53(1 290.00
	Excretion (mg)	351.11	15.02	133.88	4.75	29.93	1.08	8.62	0.36	523.55	21.21
+	Excretion rate (%)	46.81	30.03	17.85	9.51	3.99	2.16	1.15	0.73	69.81	42.42
	Concentration $(\mu g/ml)$	2,932.20	134.70	2,800.00	92.30	892.80	29.40	212.70	8.60	Ö	- 6
7		00.77			08.00		00.00		00.67		288.00
	Excretion rate (%)	20.18	10.37	190.40	97.0	00.71	2.00	15.95	0.65	492.84	19.29
	Concentration (µg/m])	3.623.60	163.30	2, 915, 60	101.60	1.155.00	39 90	272 80	10.30	17.00	20.33
	Urine volume (ml)	70.00			00.09	09	00.09	50.0		24(240.00
	Excretion (mg)	253.65		174.94	6.10	69.30				511.53	
	Excretion rate (%)	33.82	22.86	23.32	12.19	9.24	4.79	1.82	1.03	68.20	40.87
	Concentration (µg/ml)	1,780.40	96.60	3,137.40	138.30	1,221.70	37.10		9.40		
- 6	me	65.00		.09	00.09		70.00		100.00	296	295.00
	Excretion (mg)	115.73	87.01	188.24	8.30	25.52	2.60	31.97	0.94	421.46	18.11
	Concentration ("a/m])	2 098 40	120 50	01.62	138 10	1 587 60	3.19	97.79	7.00	56.19	30.23
	Urine volume (ml)	85.00	00		55.00		25.00		100 00	316	315 00
 3	Excretion (mg)	178.36	11.01			119.07			0.70	567.16	21.90
	Exerction rate(%)	23.78	22.03	32.21	15.19	15.88	5.19	3.76	1.40	75.62	43.80
Mean	Mean concentration (ng/ml)	2,601.00	123.94	2,413.02	83.57	856.40	24.97	194.85	6.22	1	1
+S.D.		1,193.60	47.06	1,026.89	37.68	461.81	12.20	92.14	3.05		1
Mean	Mean excretion rate (%)	31.62	22.55	25.58	13.13	9.66	4.22	2.62	1.21	69.48	41.11
+ 5		10.20	5.33	4.57	2.62	× ×	1.42	1.24	0.54	מני	0 53

び1週間後の計3回、シリーズ2および3については5回臨床検査を実施した。

6. 血清中および尿中濃度の測定

血清中および尿中 TIPC の濃度測定は P. aeruginosa NCTC 10701 を、また CVA 濃度測定は K. pneumoniae ATCC 29665 を検定菌とする 微生物学的定量法で行った²⁾。

7. 薬物動態の解析

各例につき BRL 28500 の成分である TIPC と CVA の血清中濃度について, シリーズ1では one-compartment open model, (Fig. 2) シリーズ2と3では two-

compartment open model (Fig. 3) にもとづき薬動力 学的解析を行った^{3~7)}。

II. 成 績

1. 安全性

(1) シリーズ1 (筋肉内投与)

BRL 28500 を1回 0.8g 筋肉内投与したときの投与 直前と投与1週間後の臨床検査値を Table 3に示した。 臨床症状および臨床検査値において、薬剤に起因すると 思われる異常は認められなかった。

(2) シリーズ2 (静注時における dose response) BRL 28500 0.8g, 1.6g および 3.2g を1回静脈内

Fig. 2 One-compartment open model for intramuscular injection

$$\begin{array}{c|c} K_a & \text{Compartment 1} \\ \hline V_d & \\ \hline \\ C_p = \frac{K_a \cdot D}{V_d(K_a - K_{el})} \cdot \{e^{-K_{el} \cdot (t - t_{lag})} - e^{-K_a \cdot (t - t_{lag})}\} \\ C_p : \text{Concentration of compartment 1 } (\mu g/ml) \\ D : \text{Dosage (mg)} \\ V_d : \text{Distribution volume (L)} \\ K_a : \text{Absorptional rate constant (hr}^{-1}) \\ K_{el} : \text{Excretional rate constant (hr}) \\ t & \text{Time after administration (hr}) \\ t_{lag} : \text{Lag time after administration (hr}) \\ \end{array}$$

Fig. 3 Two compartment open model for intravenous injection

$$\begin{array}{c|c} D & \text{Compartment 1} & K_{12} \\\hline & V_c & K_{21} \\\hline & V_t \\\hline & V_t$$

 $T_{1/2(\beta)}$: Biological half-life of β -phase (hr) $C_1(t)$: Concentration of compartment ($\mu g/ml$)

Table 10	Pharmacokinetics	parameter	of	TIPC	in	Series 1	I
----------	------------------	-----------	----	------	----	----------	---

No.	A	<i>Ka</i> (1/hr.)	<i>Kel</i> (1/hr.)	T _{1/2} (hr.)	AUC (hr·µg/ml)	T max (hr.)	C max (hr.)	Lag time (hr.)
1	57.15	1.91	0.52	1.33	79.81	0.94	25.53	0.00
2	56.67	4.49	0.65	1.06	74.22	0.50	34.90	0.00
3	134.69	0.85	0.61	1.13	60.13	1.46	15.78	0.08
4	58.53	2.61	0.59	1.17	76.72	0.74	29.35	0.00
5	131.11	0.78	0.56	1.24	65.08	1.65	15.59	0.14
6	65.48	3.80	0.76	0.92	69.43	0.53	35.13	0.00
7	50.99	2.11	0.52	1.33	73.59	0.88	24.28	0.00
8	39.41	3.21	0.52	1.32	63.01	0.67	23.18	0.00
9	129.45	0.74	0.52	1.33	71.98	1.65	16.24	0.04
10	154.63	0.84	0.57	1.21	85.10	1.56	21.34	0.12
Mean	87.81	2.13	0.58	1.20	71.91	1.06	24.13	0.04
±S.D.	43.76	1.37	0.08	0.14	7.74	0.47	7.30	0.06

Table 11 Pharmacokinetics parameter of CVA in Series I

No.	A	<i>Ka</i> (1/hr.)	<i>Kel</i> (1/hr.)	T _{1/2} (hr.)	AUC (hr·μg/ml)	T max (hr.)	C max (µg/ml)	Lag Time (hr.)
1	1.90	4.33	0.47	1.47	3.59	0.59	1.30	0.02
2	2.56	10.32	0.63	1.10	3.83	0.29	2.00	0.00
3	5.03	0.95	0.67	1.03	2.23	1.24	0.65	0.00
4	2.24	5.46	0.56	1.24	3.60	0.46	1.55	0.00
5	6.86	0.87	0.63	1.10	3.02	1.48	0.81	0.13
6	2.82	7.07	0.68	1.01	3.73	0.37	1.99	0.00
7	1.91	4.06	0.42	1.66	4.09	0.62	1.32	0.00
8	1.94	6.82	0.49	1.40	3.64	0.44	1.46	0.02
9	7.79	0.80	0.61	1.13	3.14	1.42	0.81	0.00
10	17.85	0.78	0.67	1.03	3.66	1.46	0.98	0.09
Mean	5.11	4.15	0.58	1.22	3.45	0.84	1.29	0.03
±S.D.	4.99	3.32	0.09	0.22	0.53	0.50	0.48	0.05

Fig. 4 Mean serum concentration of TIPC and CVA following IM administration of BRL 28500 (0.8 g) (n=10)





Fig. 7 Mean urinary excretion of TIPC and CVA following IV bolus administrayion of BRL 28500 (0.8g, 1.6g, 3.2g) (n=12)






Fig. 5 Mean urinary excretion of TIPC and CVA following IM administration of BRL 28500 (0.8 g) (n=10)






Fig. 6 Mean serum concentration of TIPC and CVA following IV bolus adminitration of BRL 28500 (0.8g, 1.6g, 3.2g) (n=12)





227

Time(hr.) 1/12 1/4 1/21 3/2 2 4 6 No. Drug 48.75 26.79 17.38 9.21 1.66 0.79 92.13 61.64 TIPC 11 0.52 CVA 4.87 3.38 2.42 1.34 0.88 0.11 < 0.08 77.50 52.77 34.94 23.99 14.28 3.67 1.09 TIPC 133.85 12 2.01 1.05 0.62 0.40 0.09 < 0.08 CVA 5.43 3.21 78.25 45.93 33.01 22.24 13.99 4.33 1.14 TIPC 111.05 13 0.41 < 0.08 CVA 4.95 3.27 1.96 1.09 0.62 0.08 TIPC 95.82 69.78 51.74 26.54 18.40 9.82 2.33 0.80 14 CVA 0.78 0.45 0.09 < 0.08 5.76 3.59 2.23 1.15 TIPC 31.18 18.58 11.90 2.52 0.80 123.73 62.23 46.85 15 CVA 3.16 1.96 1.10 0.67 0.43 0.10 < 0.08 5.39 TIPC 129.96 92.87 61.24 35.61 22.24 15.96 3.78 0.94 16 CVA 5.86 3.91 2.68 1.45 0.98 0.60 0.14 < 0.08 TIPC 137.85 100.62 70.36 43.05 27.39 21.62 5.57 2.13 17 CVA 1.23 0.81 < 0.085.96 4.34 3.19 1.89 0.19TIPC 61.24 37.70 27.91 18.96 2.11 126.18 82.07 5.06 18 CVA 0.79 0.22 7.93 4.11 3.06 1.75 1.27 < 0.08TIPC 120.10 65.90 51.74 28.36 17.06 10.02 1.81 0.80 19 CVA 6.01 3.65 2.55 1.31 0.84 0.58 0.12 < 0.08 TIPC 144.80 105.14 71.06 30.98 24.66 6.02 48.24 1.95 20 CVA 7.42 4.47 3.19 1.85 1.22 0.73 0.19 < 0.08 TIPC 95.84 63.92 41.88 23.78 2.33 17.42 11.54 0.92 21 CVA 5.60 3.59 1.46 1.21 0.77 0.53 0.10 < 0.08TIPC 114.75 66.66 48.7433.74 21.61 14.26 3.05 0.90 22 CVA 5.18 3.65 2.59 1.44 0.89 0.63 0.13 < 0.08 Mean 118.84 77.21 54.36 33.58 22.10 14.68 3.51 1.20 TIPC ±S.D. 17.36 15.18 9.50 7.09 4.67 4.87 0.54 1.48 Mean 5.86 3.69 2.44 1.39 0.90 0.57 0.13 < 0.08

Table 12 Serum concentration in Series II: BRL 28500 (0.8g, IV bolus)

投与したときの投与直前と投与1週間後の臨床検査値を Table 4,5 に示した。

0.93

0.43

0.54

臨床症状および臨床検査値において薬剤に起因すると 思われる異常は認められなかった。

(3) シリーズ3(薬剤相互作用)

±S.D.

CVA

臨床検査値においては,薬剤に起因すると思われる異 常は認められなかった (Table 6,7)。 なお, 臨床症状で は1例 (No. 25 K. H.) に潮紅の異常を認めた。最終投 与の CVA 投与時に薬剤との関連は明らかではないが, むくみを伴う潮紅がみられ,無処置で約1時間40分後 には完全に消失した。

その他の臨床症状の異常は認められなかった。

0.14

0.05

2. 体内動態

0.30

(1) シリーズ1 (筋肉内投与)

0.23

BRL 28500 0.8 g を1回筋注投与した場合の血清中濃 度, 尿中排泄を Table 8,9, Fig. 4,5 に示した。薬動力 学的パラメーターについては Table 10, 11 に示した。 TIPC の血中濃度は投与1時間でピークに達し、そのと きの濃度は 23.20 μg/ml であった。一方, CVA は 45分 でピークに達し、 $1.12 \mu g/ml$ を示した。また、原中濃度は TIPC, CVA ともに 0~2 時間値が最高で, それぞれ 2,601.00 μg/ml, 123.94 μg/ml であり, 0~8 時間の尿中

Table 13 Serum concentration in Series II: BRI 28500 (1.6	6 TV holu	(1 60	RI 28500	II . BB	Series	in	concentration	Serum	able 13	7
---	-----------	-------	----------	---------	--------	----	---------------	-------	---------	---

TIPC 214.99 142.34 98.04 58.33 39.82 28.42 5.99 11				Serum co	ncentration i	n Series II . I	BRL 28500 (1	.og, w boru	is)	
CVA	No.		1/12	1/4	1/2	1	3/2	2	4	6
CVA 8.91 6.27 4.54 2.40 1.54 0.92 0.33 TIPC 246.92 170.60 122.41 73.14 48.03 36.60 10.03 3 TIPC 196.43 137.07 93.65 58.30 40.28 29.80 7.88 13 CVA 9.88 6.17 3.95 1.93 1.02 0.74 0.16 14 TIPC 197.07 127.66 101.42 59.78 37.61 30.26 6.99 15 TIPC 214.95 118.62 94.88 59.61 40.84 24.69 7.53 15 TIPC 214.95 118.62 94.88 59.61 40.84 24.69 7.53 16 TIPC 248.10 147.22 121.17 68.13 40.18 32.11 8.96 17 TIPC 201.60 154.70 122.22 77.79 52.85	11	TIPC	214.99	142.34	98.04	58.33	39.82	28.42	5.99	1.16
TIPC 196.43 137.07 93.65 58.30 40.28 29.80 7.88 137.07 127.66 101.42 59.78 37.61 30.26 6.99 127.74 174.40 110.17 66.47 44.37 32.52 8.81 37.07 12.66 12.24 1.29 1.25 0.84 0.22 <	11	CVA	8.91	6.27	4.54	2.40	1.54	0.92	0.33	<0.08
CVA 12.03 8.02 4.69 2.24 1.29 0.84 0.22 TIPC 196.43 137.07 93.65 58.30 40.28 29.80 7.88 CVA 9.88 6.17 3.95 1.93 1.02 0.74 0.16 14 TIPC 197.07 127.66 101.42 59.78 37.61 30.26 6.99 15 CVA 11.33 6.95 4.11 2.50 1.53 0.99 0.27 15 CVA 10.31 6.42 3.73 2.19 1.37 0.80 0.26 16 TIPC 248.10 147.22 121.17 68.13 40.18 32.11 8.96 17 TIPC 248.10 147.22 121.17 68.13 40.18 32.11 8.96 17 TIPC 201.60 154.70 122.22 77.79 52.85 38.45 13.01	10	TIPC	246.92	170.60	122.41	73.14	48.03	36.60	10.03	2.49
CVA	12	CVA	12.03	8.02	4.69	2.24	1.29	0.84	0.22	<0.08
CVA 9.88 6.17 3.95 1.93 1.02 0.74 0.16 14 TIPC 197.07 127.66 101.42 59.78 37.61 30.26 6.99 15 CVA 11.33 6.95 4.11 2.50 1.53 0.99 0.27 15 CVA 10.31 6.42 3.73 2.19 1.37 0.80 0.26 16 CVA 10.31 6.42 3.73 2.19 1.37 0.80 0.26 16 CVA 13.00 7.59 5.04 2.54 1.42 0.98 0.31 17 TIPC 201.60 154.70 122.22 77.79 52.85 38.45 13.01 3 18 TIPC 236.52 157.07 119.00 76.41 53.46 40.24 12.29 3 18 TIPC 236.52 157.07 119.00 76.41 53.46 40.24 </td <td>12</td> <td>TIPC</td> <td>196.43</td> <td>137.07</td> <td>93.65</td> <td>58.30</td> <td>40.28</td> <td>29.80</td> <td>7.88</td> <td>1.89</td>	12	TIPC	196.43	137.07	93.65	58.30	40.28	29.80	7.88	1.89
14 CVA 11.33 6.95 4.11 2.50 1.53 0.99 0.27 15 TIPC 214.95 118.62 94.88 59.61 40.84 24.69 7.53	13	CVA	9.88	6.17	3.95	1.93	1.02	0.74	0.16	<0.08
CVA 11.33 6.95 4.11 2.50 1.53 0.99 0.27 < TIPC 214.95 118.62 94.88 59.61 40.84 24.69 7.53 7.54 7.42 7.98 7.53 7.11 8.96 7.77 7.58 7.53 7.53 7.53 7.53 7.53 7.53 7.53 7.53 7.53 7.53 7.53 7.53 7.53 7.53 7.54 7.77 7.59 7.88 7.53 <td>14</td> <td>TIPC</td> <td>197.07</td> <td>127.66</td> <td>101.42</td> <td>59.78</td> <td>37.61</td> <td>30.26</td> <td>6.99</td> <td>1.91</td>	14	TIPC	197.07	127.66	101.42	59.78	37.61	30.26	6.99	1.91
TIPC 248.10 147.22 121.17 68.13 40.18 32.11 8.96 CVA 13.00 7.59 5.04 2.54 1.42 0.98 0.31 CVA 11.53 7.23 5.21 3.03 1.96 1.15 0.41 0.29 CVA 12.88 8.90 6.04 3.70 2.26 1.39 0.44 0.18 CVA 12.88 8.90 6.04 3.70 2.26 1.39 0.44 0.20 CVA 10.85 7.41 4.69 2.59 1.51 0.91 0.26 CVA 12.88 8.69 5.43 2.95 1.76 1.01 0.29 CVA 12.80 13.05 111.35 61.24 48.70 32.37 7.96 1.02 CVA 12.81 13.05 111.35 61.24 48.70 32.37 7.96 1.02 CVA 10.15 6.71 4.94 2.97 1.85 1.12 0.32 CVA 10.15 6.71 4.94 2.97 1.85 1.12 0.32 CVA 11.00 Mean 217.74 174.40 110.17 66.47 44.37 32.52 8.81	14	CVA	11.33	6.95	4.11	2.50	1.53	0.99	0.27	<0.08
CVA 10.31 6.42 3.73 2.19 1.37 0.80 0.26 TIPC 248.10 147.22 121.17 68.13 40.18 32.11 8.96 32.11 8.96 32.11 8.96 33.11 8.96 33.11 8.96 33.11 40.18 32.11 8.96 33.11 40.18 32.11 8.96 33.11 40.18 32.11 8.96 33.11 40.18 32.11 8.96 33.11 40.18 32.11 8.96 33.11 40.18 32.11 8.96 33.11 40.18 32.11 8.96 33.11 40.18 32.11 8.96 33.11 40.18 32.11 8.96 33.11 40.11	15	TIPC	214.95	118.62	94.88	59.61	40.84	24.69	7.53	1.78
16 CVA 13.00 7.59 5.04 2.54 1.42 0.98 0.31 C 17 TIPC 201.60 154.70 122.22 77.79 52.85 38.45 13.01 3 CVA 11.53 7.23 5.21 3.03 1.96 1.15 0.41 0 18 TIPC 236.52 157.07 119.00 76.41 53.46 40.24 12.29 3 18 CVA 12.88 8.90 6.04 3.70 2.26 1.39 0.44 0 19 TIPC 214.00 144.50 96.55 59.87 38.31 27.07 5.99 3 20 TIPC 243.73 198.65 149.80 92.09 60.04 47.31 13.55 3 21 TIPC 193.06 137.35 91.51 52.95 32.35 22.87 5.57 21 TIPC 193.06 137.35 91.51 52.95 32.35 <td>15</td> <td>CVA</td> <td>10.31</td> <td>6.42</td> <td>3.73</td> <td>2.19</td> <td>1.37</td> <td>0.80</td> <td>0.26</td> <td><0.08</td>	15	CVA	10.31	6.42	3.73	2.19	1.37	0.80	0.26	<0.08
CVA 13.00 7.59 5.04 2.54 1.42 0.98 0.31 <0 17 TIPC 201.60 154.70 122.22 77.79 52.85 38.45 13.01 3 18 TIPC 236.52 157.07 119.00 76.41 53.46 40.24 12.29 3 19 TIPC 218.88 8.90 6.04 3.70 2.26 1.39 0.44 0 20 TIPC 214.00 144.50 96.55 59.87 38.31 27.07 5.99 3 20 TIPC 243.73 198.65 149.80 92.09 60.04 47.31 13.55 3 20 TIPC 243.73 198.65 149.80 92.09 60.04 47.31 13.55 3 21 TIPC 193.06 137.35 91.51 52.95 32.35 22.87 5.57 3	16	TIPC	248.10	147.22	121.17	68.13	40.18	32.11	8.96	1.85
17 CVA 11.53 7.23 5.21 3.03 1.96 1.15 0.41 0 18 TIPC 236.52 157.07 119.00 76.41 53.46 40.24 12.29 3 CVA 12.88 8.90 6.04 3.70 2.26 1.39 0.44 0 19 TIPC 214.00 144.50 96.55 59.87 38.31 27.07 5.99 3 CVA 10.85 7.41 4.69 2.59 1.51 0.91 0.26 <0	10	CVA	13.00	7.59	5.04	2.54	1.42	0.98	0.31	<0.08
CVA 11.53 7.23 5.21 3.03 1.96 1.15 0.41 0.42 12.29 3.22 0.41 0.42 12.29 3.23 0.44 0.22 0.44 0.42 12.29 0.44	17	TIPC	201.60	154.70	122.22	77.79	52.85	38.45	13.01	3.24
18 CVA 12.88 8.90 6.04 3.70 2.26 1.39 0.44 0 19 TIPC 214.00 144.50 96.55 59.87 38.31 27.07 5.99 1 20 CVA 10.85 7.41 4.69 2.59 1.51 0.91 0.26 20 TIPC 243.73 198.65 149.80 92.09 60.04 47.31 13.55 3 CVA 12.88 8.69 5.43 2.95 1.76 1.01 0.29 21 TIPC 193.06 137.35 91.51 52.95 32.35 22.87 5.57 3 CVA 9.63 7.25 3.91 1.95 1.25 0.81 0.21 22 TIPC 205.57 133.05 111.35 61.24 48.70 32.37 7.96 1 24 TIPC 205.57 137.40 110.17 66.47 44.37	17	CVA	11.53	7.23	5.21	3.03	1.96	1.15	0.41	0.10
CVA 12.88 8.90 6.04 3.70 2.26 1.39 0.44 0.27 5.99 3.83 1.27.07 5.99 3.99 3.91 1.51 0.91 0.26 0.26 0.04 0.26 0.04 0.26 0.04 0.26 0.04	10	TIPC	236.52	157.07	119.00	76.41	53.46	40.24	12.29	3.87
19 CVA 10.85 7.41 4.69 2.59 1.51 0.91 0.26 <	10	CVA	12.88	8.90	6.04	3.70	2.26	1.39	0.44	0.15
CVA 10.85 7.41 4.69 2.59 1.51 0.91 0.26 <0 20 TIPC 243.73 198.65 149.80 92.09 60.04 47.31 13.55 3 CVA 12.88 8.69 5.43 2.95 1.76 1.01 0.29 <0	10	TIPC	214.00	144.50	96.55	59.87	38.31	27.07	5.99	1.07
20 CVA 12.88 8.69 5.43 2.95 1.76 1.01 0.29 21 TIPC 193.06 137.35 91.51 52.95 32.35 22.87 5.57 5.57 CVA 9.63 7.25 3.91 1.95 1.25 0.81 0.21 <0	19	CVA	10.85	7.41	4.69	2.59	1.51	0.91	0.26	<0.08
CVA 12.88 8.69 5.43 2.95 1.76 1.01 0.29 <0 21 TIPC 193.06 137.35 91.51 52.95 32.35 22.87 5.57 <t< td=""><td>20</td><td>TIPC</td><td>243.73</td><td>198.65</td><td>149.80</td><td>92.09</td><td>60.04</td><td>47.31</td><td>13.55</td><td>3.24</td></t<>	20	TIPC	243.73	198.65	149.80	92.09	60.04	47.31	13.55	3.24
21 CVA 9.63 7.25 3.91 1.95 1.25 0.81 0.21 < 22 TIPC 205.57 133.05 111.35 61.24 48.70 32.37 7.96 1 CVA 10.15 6.71 4.94 2.97 1.85 1.12 0.32 <	20	CVA	12.88	8.69	5.43	2.95	1.76	1.01	0.29	<0.08
CVA 9.63 7.25 3.91 1.95 1.25 0.81 0.21 <0 22 TIPC 205.57 133.05 111.35 61.24 48.70 32.37 7.96 1 CVA 10.15 6.71 4.94 2.97 1.85 1.12 0.32 <0	01	TIPC	193.06	137.35	91.51	52.95	32.35	22.87	5.57	1.37
22 CVA 10.15 6.71 4.94 2.97 1.85 1.12 0.32 <0 TIPC Mean 217.74 174.40 110.17 66.47 44.37 32.52 8.81 32.52	21	CVA	9.63	7.25	3.91	1.95	1,25	0.81	0.21	<0.08
CVA 10.15 6.71 4.94 2.97 1.85 1.12 0.32 <0 TIPC Mean 217.74 174.40 110.17 66.47 44.37 32.52 8.81 32		TIPC	205.57	133.05	111.35	61.24	48.70	32.37	7.96	1.89
TIPC	22	CVA	10.15	6.71	4.94	2.97	1.85	1.12	0.32	<0.08
	TIDC	Mean	217.74	174.40	110.17	66.47	44.37	32.52	8.81	2.15
±S.D. 20.74 21.27 17.40 11.32 8.13 7.03 2.81	1111	±S.D.	20.74	21.27	17.40	11.32	8.13	7.03	2.81	0.89
CVA Mean 11.11 7.30 4.69 2.58 1.56 0.97 0.29	CVA	Mean	11.11	7.30	4.69	2.58	1.56	0.97	0.29	<0.08
±S.D. 1.38 0.89 0.69 0.51 0.34 0.18 0.08	CVA	±S.D.	1.38	0.89	0.69	0.51	0.34	0.18	0.08	

排泄率は TIPC, CVA でそれぞれ 69.48%, 41.11% という結果が得られた。

(2) シリーズ 2 (静注時における dose response) BRL 28500 0.8 g, 1.6 g および 3.2 g を静脈内投与した場合の血清中濃度,尿中排泄および薬動力学的パラメーターを Table 12, 13, 14, 15, 16, 17, 18, 19, Fig. 6, Fig. 7 に示した。BRL 28500 0.8 g, 1.6 g, 3.2 g を静脈内に 1 回投与した場合の 5 分後の TIPC 血清中濃度はそれ ぞれ 118.84, 217.74 および 404.34 μg/ml, CVA 血清中濃度は 5.86, 11.11 および 20.89 μg/ml であった。また,AUC は TIPC では 108.01, 217.67 お

よび $469.05 \text{ hr} \cdot \mu g/\text{ml}$, CVA では 4.60, $8.62 \times \text{J}$ $\sqrt{18.52 \text{ hr}} \cdot \mu g/\text{ml}$ であった。TIPC, CVA 共に 5 分後の血清中濃度と AUC はほぼ用量に比例し、dose response がみられた。血清中濃度半減期 $(T_{1/2}\alpha, T_{1/2}\beta)$ はTIPC では (0.16, 0.97), (0.16, 1.02) および (0.10, 1.06) 時間、CVA では (0.14, 0.83), (0.18, 0.93) および (0.18, 0.97) 時間 で投与量にかかわらずほぼ一定であった。また、尿中濃度は TIPC、CVA ともに $0\sim2$ 時間 が最高で、0.8g 投与ではそれ ぞれ $2.480.09\,\mu g/\text{ml}$, $121.44\,\mu g/\text{ml}$, 1.6g 投与では $4.937.98\,\mu g/\text{ml}$, $228.13\,\mu g/\text{ml}$, 3.2g 投与では $9.665.49\,\mu g/\text{ml}$, $481.12\,\mu g/\text{rb}$

		Table 14	Serum cor	ncentration in	n Series II:I	BRL28500 (3	.2g, IV bolu	s)	
No.	Time(hr.) Drug	1/12	1/4	1/2	1	3/2	2	4	6
	TIPC	317.34	263.08	157.63	118.94	73.32	45.31	9.39	1.65
11	CVA	15.71	13.22	8.32	5.25	3.34	2.16	0.45	0.11
	TIPC	405.66	314.49	200.46	144.26	107.31	82.20	19.95	4.44
12	CVA	19.36	13.93	8.32	4.48	2.98	2.33	0.43	0.10
	TIPC	343.28	230.87	177.77	114.20	86.45	61.18	14.89	3.68
13	CVA	17.08	11.13	6.98	3.93	2.37	1.65	0.28	< 0.08
	TIPC	400.67	216.05	202.33	132.84	99.38	63.52	16.57	4.12
14	CVA	20.02	12.66	8.18	5.30	3.67	2.21	0.47	0.10
	TIPC	370.74	253.00	180.05	134.70	97.79	66.57	17.31	3.97
15	CVA	19.52	12.88	8.60	4.75	3.34	2.02	0.46	0.09
- 10	TIPC	425.38	276.92	223.88	155.25	104.47	87.76	23.37	5.30
16	CVA	23.00	15.99	10.41	6.17	3.99	3.10	0.67	0.17
17	TIPC	359.21	318.03	230.97	167.35	120.09	112.36	33.79	13.02
17	CVA	23.86	16.84	10.94	6.44	4.17	3.46	0.89	0.29
10	TIPC	425.67	299.80	209.04	154.25	127.58	106.13	30.74	12.44
18	CVA	22.28	18.20	11.50	7.08	4.58	3.46	0.85	0.36
19	TIPC	462.27	243.98	216.20	126.98	82.01	64.72	15.60	3.68
19	CVA	22.88	13.45	9.66	5.52	3.34	2.39	0.62	0.15
20	TIPC	545.90	376.96	297.65	210.27	151.64	127.52	33.10	10.45
	CVA	24.01	17.89	11.21	6.52	3.99	3.23	0.69	0.20
21	TIPC	372.75	269.41	194.45	116.61	92.75	62.27	14.29	3.72
	CVA	21.14	13.83	5.83	4.42	2.97	2.18	0.53	0.13
22	TIPC	423.18	317.10	234.07	148.61	120.29	85.58	21.19	5.33
	CVA	21.81	14.16	10.42	6.19	4.36	3.27	0.71	0.18
TIPC	Mean	404.34	281.64	210.37	143.69	105.26	80.43	20.85	5.98
	±S.D.	60.40	45.44	35.68	26.89	21.87	24.57	7.93	3.77
CVA	Mean	20.89	14.51	9.20	5.50	3.59	2.62	0.59	0.16
J	100			1	1		1	1	1

り、ほぼ用量に比例した dose response がみられた。一 方,0~8時間の尿中回収率は用量にかかわらずほぼ一定 で、TIPC では約 76%、CVA では約 49% であった。

2.63

2.21

1.78

0.99

0.65

(3) シリーズ3(薬剤相互作用)

±S.D.

BRL 28500 は合剤であるので、 その 組成分で ある TIPC と CVA がお互いの吸収・排泄に及ぼす影響を検 討した。使用 した 薬剤は TIPC (単独) 3.0 g, CVA-K (単独) 0.2g および BRL 28500 (合剤) 3.2g で, これ らを triple cross over 法で投与し、薬剤相互作用 を検 討した (Table 20, 21, 22, 23, 24, 25, 26, 27, Fig. 8, 9)

BRL 28500 (合剤) 3.2g および TIPC (単独) 3.0g をそれぞれ投与した時の5分後の TIPC 血清中濃度は、 合剤投与時 408.81 μg/ml, 単独投与時 420.72 μg/ml で あり、AUC は合剤で 473.13 hr·μg/ml, 単独では510.32 $hr \cdot \mu g/ml$ であった。また血清中濃度半減期 $(T_{1/2}\alpha,$ $T_{1/2}\beta$) は合剤で (0.15, 1.08), 単独では (0.12, 1.08) 時間であった。BRL 28500 (合剤) 3.2g および CVA-K (単独) 0.2g をそれぞれ投与した時の5分後の CVA 血 清中濃度は、合剤で 20.19 μ g/ml、単独では 19.49 μ g/ml であり、AUC は合剤で 17.44 hr·μg/ml, 単独ては16.20 hr·μg/ml であった。半減期は合剤で (0.19, 1.01), 単

0.64

0.18

6.09

Table 15 Urinary concentration in Series II: BRL 28500 (0.8g, IV bolus)

-											
2	Time(hr.)		0-2	2-4			4-6	8-9		- [8-0
	Item	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA
	Concentration (µg/ml)	1,873.30	118.00	295.10	12.80	53.80	2.60	21.60	1.10		
	Urine volume (ml)	215.00	.00	290.00	.00	292	295.00	185	185.00	586	985.00
	Excretion (mg)	402.76	25.37	85.58	3.71	15.87	<i>LL</i> 0	4.00	0.20	508.21	30.02
	Excretion rate (%)	53.70		11.41	7.42	2.12	1.53	0.53	0.41	92.79	60.11
	Concentration (µg/ml)	2,879.40	112.90	645.50	15.10	143.90	3.00	51.10	1.10		
10	Urine volume (ml)	160.00		145.00	.00	165	165.00	120	120.00	290	590.00
····	Excretion (mg)	460.70	18.06	93.60	2.19	23.74	0.50	6.13	0.13	584.18	20.88
	Excretion rate (%)	61.43		12.48	4.38	3.17	66.0	0.82	0.26	68.77	41.76
	Concentration $(\mu g/ml)$	3,657.40	179.20	1,266.90	26.20	431.10	7.30	117.20	1.30		
	Urine volume (ml)	110.00	.00	06	90.00	02	70.00		70.00	340	340.00
	Excretion (mg)	402.31	19.71	114.02	2.36	30.18	0.51	8.20	60.0	554.72	22.67
	Excretion rate (%)	53.64	39.42	15.20	4.72	4.02	1.02	1.09	0.18	73.96	45.34
	Concentration (µg/ml)	3,191.10	146.90	1,591.50	47.60	359.10	9.60	111.70	2.70		
	Urine volume (ml)	155.00	.00	09	00.09	02	70.00	20	50.00	335	335.00
	Excretion (mg)	494.62		95.49	2.86	25.14	29.0		0.14	620.83	
	Excretion rate (%)	65.95	45.54	12.73	5.71	3.35	1.34	0.74	0.27	82.78	52.87
	Concentration (µg/ml)	2,102.10	88.90	1,327.20	38.80	127.40	3.60	30.50	08.0		
-	Urine volume (ml)	200.00	.00	92	65.00	160	00:	135	135.00	260	560.00
	Excretion (mg)	420.42		86.27	2.52	20.38	3 0.58	4.12	0.11	531.19	
	Excretion rate (%)	56.06		11.50	5.04	2.72	1.15	0.55	0.22	70.83	41.97
	Concentration (µg/ml)	2,282.30	98.70	396.20	11.90	77.50	2.10	37.00	1.00		
4	Urine volume (ml)	185.00	.00	240.00		315	315.00	195	195.00	932	935.00
	Excretion (mg)	422.23	18.26	95.09	2.86	24.41	99.0	7.22	0.20	548,94	21.97
	Excretion rate (%)	56.30	36.52	12.68	5.71	3.26	1.32	96.0	0.39	73,19	43.94
-	Concentration (µg/ml)	4,023.70	233.30	1,800.10	53.70	187.00	4.20	115.50	2.50		
-	Urine volume (ml)	105.00	00:	02	70.00	210	210.00	100	100.00	485	485.00
	Excretion (mg)	422.49		126.01	3.76	39.27		11.55	0.25	599.32	
	Excretion rate (%)	56.33	48.99	16.80	7.52	5.24	1.76	1.54	0.50	79.91	58,78
	Concentration (µg/ml)	1,132.00	29.50	493.10	15.90	213.00	7.80	48.60	2.00		
	Urine volume (ml)	385.00	.00	230.00	.00		160.00	240.00	00:	1,015.00	.00
	Excretion (mg)	435.82	22.91	113.41	3.66	34.21	1.25	4.60	0.28	590.25	28.09
	Excretion rate (%)	58.11	45.82	15.12	7.31	4.56	2.50	0.91	0.56	78.70	56.18
	Concentration (µg/ml)	2,077.10	102.30	1,267.90	48.10	269.20	12.50	52.10	2.40		
- 0	ıme	230	230.00	75	75.00		78.00		83.00	466.00	00
,	Excretion (mg)	477.73	23.53	95.09	3.61	21.00	0.98	4.32	0.20	598.15	28.31

Table 15-2

 /	····	0-2	2	5-4	7	4-6	9	8-9	œ,	8-0	∞
Item	7	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA
Concentration (µg/ml)	(lm/gr	2,137.40	93.40	264.50	6.70	126.30	2.70	41.00	08.0		
Urine volume (ml)	nl)	190.00	00	410.00	00.	265	265.00	250	250,00	1,11	1,115.00
Excretion (mg)	ng)	406.11	17.75	108.45	2.75	33.47	0.72	10.25	0.20	558.27	21.41
Excretion rate (%)	(%	54.15	35.49	14.46	5.49	4.46	1.43	1.37	0.40	74.44	42.82
Concentration (µg/ml)	(lm/g)	2,637.80	134.40	757.00	24.90	133.40	4.10	43.40	1.00		
Urine volume (ml)		170.00	00	125.00	00:	185	185.00	140	140.00	629	620.00
Excretion (m	(mg)	448.43	22.85	94.63	3.11	24.68	0.76	00.9	0.14	573.81	26.86
Excretion rate (%)	(%)	59.79	45.70	12.62	6.23	3.29	1.52	0.81	0.28	76.51	53.72
Concentration (µg/ml)	(g/ml)	1,767.50	89.80	529.00	20.60	75.30	2.70	40.20	1.40		
Urine volume (ml)	ul)	240.00	00	180,00	00:	320	320.00		170.00	16	910.00
Excretion (m	(mg)	424.20	21.55	95.22	3.71	24.10	98.0	6.83	0.24	550,35	26.36
Excretion rate (%)	(%)	56.56	43.10	12.70	7.42	3.21	1.73	0.91	0.48	73.38	52.72
Mean concentration (µg/ml)	(ml)	2,480.09	121.44	886.17	26.86	183.08	5.18	59.16	1.51		
		831.97	47.02	535.17	16.16	117.02	3.33	34.63	0.70		1
Mean excretion rate (%)		57.97	42.50	13.37	6.17	3.52	1.52	0.95	0.41	75.80	50.59
		3.98	2.60	1.65	1.16	0.88	0.43	0.38	0.21	4.32	96.9

Table 16 Urinary concentration in Series II: BRL 28500 (1.6g, N bolus)

	H:			,						0	
Ž	I ime (hr.)	0	2-0	.7	2-4	4-p		Ω_0		-	
Ö.	Item	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	THPC	CVA
	Concentration (µg/ml)	6,216.60	340.80	888.00	35.10	420.10	15.80	168.10	6.10	_	
=======================================	Urine volume (ml)	145	145.00	200.00	00:	100.00	00	42.00		490.00	
1	Excretion (mg)	901.41	49.42	177.60	7.02	42.01	1.58	7.56	0.27	1,128.58	58.29
	Excretion rate (%)	60.09	49.42	11.84	7.02	2.80	1.58	0.50	0.27	75.24	58.29
	Concentration (µg/ml)	6,892.50	254.00	4,828.30	74.90	320.20	5.50	129.80	2.30	_	
9	Urine volume (ml)	145.00	00.	22	55.00	250.00	00	100.00	0	550.00	00
77	Excretion (mg)	999.41	36.83	265.56	4.12	80.05	1.38	12.98	0.23	1,358.00	42.55
	Excretion rate (%)	66.63	36.83	17.70	4.12	5.34	1.38	0.87	0.23	90.53	42.55
	Concentration (µg/ml)	4,202.50	170.10	3,317.90	58.70	971.60	13.10	173.90	2.50		
	Urine volume (ml)	210	210.00	02	70.00	85.00	00	80.00	0	445.00	00.
13	Excretion (mg)	882.53	35.72	232.25	4.11	82.59	1.11	13.91	0.20	1,211.28	41.14
	Excretion rate (%)	58.84	35.72	15.48	4.11	5.51	1.11	0.93	0.20	80.75	41.14
	Concentration (µg/ml)	4,316.30	281.70	927.40	27.90	559.00	11.90	195.60	3.10		
:	Urine volume (ml)	160	160.00	235	235.00	140.00	00	70.00	, 0	605.00	.00
	Excretion (mg)	19.069	45.07	217.94	6.56	78.26	1.67	13.69	0.22	1,000.50	53.51
-	Excretion rate (%)	46.04	45.07	14.53	6.56	5.22	1.67	0.91	0.22	02.99	53.51
	Concentration (µg/ml)	5,126.50	188.00	1,843.60	41.30	215.00	5.60	112.50	2.20	_	
ļ	Urine volume (ml)	195.00	.00	140.00	00:	275.00	00	145.00	0	755.00	00.
	Excretion (mg)	29.666	36.66	258.10	5.78	59.13	1.54	16.31	0.32	1,333.21	44.30
	Excretion rate (%)	66.64	36.66	17.21	5.78	3.94	1.54	1.09	0.32	88.88	44.30
	Concentration (µg/ml)	6,152.50	256.50	3,747.90	62.70	624.90	12.10	148.10	2.90		
,	Urine volume (ml)	135.00	.00	9	65.00	00.06	00	00.06	0	380.00	.00
91	Excretion (mg)	830.59	34.63	243.61	4.08	56.24	1.09	13.33	0.26	1,143.77	40.05
	Excretion rate (%)	55.37	34.63	16.24	4.08	3.75	1.09	0.89	0.26	76.25	40.05
	Concentration (µg/ml)	5,181.10	228.00	3,761.90	84.40	799.30	16.00	60.30	1.50	_	
1	Urine volume (m1)	140.00	.00	52	55.00	100.00	00	370.00	0	999	665.00
	Excretion (mg)	725.35	31.92	206.90	4.64	79.93	1.60	22.31	0.56	1,034.50	38.72
	Excretion rate (%)	48.36	31.92	13.79	4.64	5.33	1.60	1.49	0.56	68.97	38.72
	Concentration (µg/ml)	1,908.90	116.90	601.60	23.10	238.90	8.00	110.90	3.80		
	Urine volume (ml)	400.00	.00	410.00	00.	130.00	00	240.00	0	1,180.00	.00
δ <u>I</u>	Excretion (mg)	763.56	46.76	246.66	9.47	31.06	1.04	26.62	0.91	1,067.89	58.18
	Excretion rate (%)	50.90	46.76	16.44	9.47	2.07	1.04	1.77	0.91	71.19	58.18
	Concentration (µg/ml)	2,774.40	141.70	1,726.20	49.00	377.80	12.90	123.80	2.60		
	Urine volume (ml)	355.00		115	115.00	175.00		95.00		740	740.00
	Excretion (mg)	984.91	50.30	198.51	5.64	66.11	2.26	11.76	0.53	1,261.30	58.73
_	Excretion rate (%)	99.59	50.30	13.23	5.04	4.41	7.50	0.10	0.00	20:40	2

Table 16-2

0-2 2-4 CVA TIPC CVA 72.30 2,813.10 51.60 470.00 33.98 281.31 5.16 451.60 3,763.20 124.40 90.00 90.00 55.00 55.00 6.84 40.64 206.98 6.84 6.84 40.64 13.80 6.84 6.84 40.64 13.80 6.84 6.84 40.12 243.75 8.94 8.94 40.12 243.75 8.94 8.94 40.12 16.25 8.94 8.94 40.17 15.75.24 31.84 31.84 40.17 15.43 6.02 6.02 6.30 2.05 1.82 1.82												
Tipc CVA Tipc CVA CVA	14	Time (hr.)	0	2	7-7	-	4-6	9	8-9	8	8-0	
Concentration (μg/ml) 1,646.90 72.30 2,813.10 51.60 Urine volume (ml) 774.04 33.98 281.31 5.16 Excretion rate (%) 51.60 33.98 18.75 5.16 Excretion rate (%) 51.60 33.98 18.75 5.16 Concentration (μg/ml) 9,864.30 451.60 3,763.20 124.40 Urine volume (μg/ml) 887.79 40.64 206.98 6.84 Excretion rate (%) 59.19 40.64 13.80 6.84 Concentration (μg/ml) 1,973.30 236.00 3,046.90 111.70 Urine volume (ml) 845.46 40.12 243.75 8.94 Excretion rate (%) 56.36 40.12 16.25 8.94 Acan concentration (μg/ml) 4,937.98 228.13 2,605.56 62.07 S.D. 57.14 40.17 15.43 6.02 S.D. 57.14 40.17 15.35 1.82	o N	Item	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA
Urine volume (ml) 470.00 100.00 Excretion (mg) 774.04 33.98 281.31 5.16 Excretion rate (%) 51.60 33.98 18.75 5.16 Concentration (μg/ml) 9,864.30 451.60 3,763.20 124.40 Urine volume (μg/ml) 887.79 40.64 206.98 6.84 Excretion rate (%) 59.19 40.64 13.80 6.84 Concentration (μg/ml) 4,973.30 236.00 3,046.90 111.70 Urine volume (ml) 845.46 40.12 243.75 8.94 Excretion rate (%) 56.36 40.12 243.75 8.94 Aean concentration (μg/ml) 4,937.98 228.13 2,605.56 62.07 S.D. 2.274.55 102.75 1,375.24 31.84 Aean excretion rate (%) 57.14 40.17 15.43 6.02 S.D. 50.05 6.30 2.65 1.82		Concentration (µg/ml)	1,646.90	72.30	2,813.10	51.60	431.20	7.70	76.20	1.40		
Excretion (mg) 774.04 33.98 281.31 5.16 Excretion rate (%) 51.60 33.98 18.75 5.16 Concentration (μg/ml) 9,864.30 451.60 3,763.20 124.40 124.40 Urine volume (μg/ml) 987.79 40.64 206.98 6.84 Excretion rate (%) 59.19 40.64 13.80 6.84 Concentration (μg/ml) 4,973.30 236.00 3,046.90 111.70 Urine volume (ml) 845.46 40.12 243.75 8.94 Excretion rate (%) 56.36 40.12 16.25 8.94 Excretion rate (%) 2,274.55 102.75 1,375.24 31.84 Gan concentration (μg/ml) 4,937.98 228.13 2,605.56 62.07 3 S.D. 2,274.55 102.75 1,375.24 31.84 3 S.D. 5.03 5.05 1,375.24 1.80	8	Urine volume (ml)	470	.00	100.	00.	190	190.00	280	280.00	1,040.00	00
Excretion rate (%) 51.60 33.98 18.75 5.16 Concentration (μg/ml) 9,864.30 451.60 3,763.20 124.40 124.40 Urine volume (μg/ml) 90.00 55.00 6.84 Excretion rate (%) 59.19 40.64 206.98 6.84 Excretion rate (%) 1, 973.30 236.00 3,046.90 111.70 Urine volume (ml) 845.46 40.12 243.75 8.94 Excretion rate (%) 56.36 40.12 16.25 8.94 Excretion rate (%) 4,937.98 228.13 2,605.56 62.07 3.50. S.D. 2,274.55 102.75 1,375.24 31.84 3.50. S.D. 5.00 5.05 5.05 1.82 3.50.	₹	Excretion (mg)	774.04	33.98	281.31	5.16	81.93	1.46	21.34	0.39	1,158.62	41.00
Concentration (μg/ml) 9,864.30 451.60 3,763.20 124.40 Urine volume (μg/ml) 99.00 55.00 Excretion (mg) 887.79 40.64 206.98 6.84 Excretion rate (%) 59.19 40.64 13.80 6.84 Concentration (μg/ml) 4,973.30 236.00 3,046.90 111.70 Urine volume (ml) 845.46 40.12 243.75 8.94 Excretion (mg) 845.46 40.12 243.75 8.94 Ban concentration (μg/ml) 4,937.98 228.13 2,605.56 62.07 S.D. 2,274.55 102.75 1,375.24 31.84 Ann excretion rate (%) 57.14 40.17 15.43 6.02 S.D. 5.03 5.05 1.83 1.84		Excretion rate (%)	51.60	33.98	18.75	5.16	5.46	1.46	1.42	0.39	77.24	41.00
Urine volume (μg/) 90.00 55.00 Excretion (mg) 887.79 40.64 206.98 6.84 Excretion rate (%) 59.19 40.64 13.80 6.84 Concentration (μg/ml) 4,973.30 236.00 3,046.90 111.70 Urine volume (ml) 845.46 40.12 243.75 8.94 Excretion rate (%) 56.36 40.12 16.25 8.94 Aean concentration (μg/ml) 4,937.98 228.13 2,605.56 62.07 3 S.D. 2,274.55 102.75 1,375.24 31.84 6.02 S.D. 7.02 6.30 2.05 1.83 1.83 3		Concentration (µg/ml)	9,864.30	451.60	3,763.20	124.40	800.80	19.50	153.80	3.80		
Excretion (mg) 887.79 40.64 206.98 6.84 Excretion rate (%) 59.19 40.64 13.80 6.84 Concentration (μg/ml) 4,973.30 236.00 3,046.90 111.70 Urine volume (ml) 845.46 40.12 243.75 8.94 Excretion (mg) 845.46 40.12 243.75 8.94 Aean concentration (μg/ml) 4,937.98 228.13 2,605.56 62.07 S.D. 2,274.55 102.75 1,375.24 31.84 Aean excretion rate (%) 57.14 40.17 15.43 6.02 S.D. 5.00 2.05 1.87 1.82	5	Urine volume (µg/	06	.00	55.	00	95	95.00	06	90.00	330.00	00
Excretion rate (%) 59.19 40.64 13.80 6.84 Concentration (µg/ml) 4,973.30 236.00 3,046.90 111.70 Urine volume (ml) 170.00 845.46 40.12 243.75 8.94 Excretion rate (%) 56.36 40.12 16.25 8.94 Acan concentration (µg/ml) 4,937.98 228.13 2,605.56 62.07 S.D. Acan excretion rate (%) 2,274.55 102.75 1,375.24 31.84 Acan excretion rate (%) 7.02 6.30 2.05 1.83 Concentration rate (%) 7.02 6.30 2.05 Concentration rate (%) 7.02 6.30 Concentration rate (%) 7.02 6.30 2.05 1.83 Concentration rate (%) 7.02 6.30 2.05 Concentration rate (%) 7.02 6.30 Concentration rate (%) 7.02 7.02 Concentration rate (%) 7.02 7.03 Concentration rate (%) 7.02 7.03 Concentration rate (%) 7.03 7.03 Concentration rate (17	Excretion (mg)	887.79	40.64	206.98	6.84	76.08	1.85	13.84	0.34	1,184.68	49.68
Concentration (μg/ml) 1, 973.30 236.00 3,046.90 111.70 Urine volume (ml) 170.00 80.00 Excretion (mg) 845.46 40.12 243.75 8.94 Excretion rate (%) 56.36 40.12 16.25 8.94 Aean concentration (μg/ml) 4,937.98 228.13 2,605.56 62.07 S.D. 2,274.55 102.75 1,375.24 31.84 Aean excretion rate (%) 57.14 40.17 15.43 6.02 S.D. 7.02 6.30 2.05 1.83		Excretion rate (%)	59.19	40.64	13.80	6.84	5.07	1.85	0.92	0.34	78.98	49.68
Urine volume (ml) 170.00 80.00 Excretion (mg) 845.46 40.12 243.75 8.94 Excretion rate (εβ) 56.36 40.12 16.25 8.94 Aem concentration (μg/ml) 4,937.98 228.13 2,665.56 62.07 5 S.D. 2,274.55 102.75 1,375.24 31.84 2 Aean excretion rate (%) 57.14 40.17 15.43 6.02 S.D. 6.30 2.05 1.82		Concentration (µg/ml)	4,973.30	236.00	3,046.90	111.70	400.40	10.60	162.90	5.20		
Excretion (mg) 845.46 40.12 243.75 8.94	8	Urine volume (ml)	170	.00	.08	00.	210.00	00:	06	90.00	550.00	00
Exerction rate (%) 56.36 40.12 16.25 8.94 concentration (μg/ml) 4,937.98 228.13 2,605.56 62.07 51 2,274.55 102.75 1,375.24 31.84 23 excretion rate (%) 57.14 40.17 15.43 6.02 7.02 6.30 2.05 1.82	77	Excretion (mg)	845.46	40.12	243.75	8.94	84.08	2.23	14.66	0.47	1,187.96	51.75
concentration (µg/ml) 4,937.98 228.13 2,605.56 62.07 51 2,274.55 102.75 1,375.24 31.84 24 excretion rate (%) 57.14 40.17 15.43 6.02 7.02 6.30 2.05 1.82		Excretion rate (%)	56.36	40.12	16.25	8.94	5.61	2.23	0.98	0.47	79.20	51.75
excretion rate (%) 57.14 40.17 15.43 6.02 7.02 6.30 2.05 1.82	Me	an concentration (µg/ml)	4,937.98	228.13	2,605.56	62.07	513.27	11.56	134.66	3.37		
excretion rate (%) 57.14 40.17 15.43 6.02 7.02 6.30 2.05 1.82	+S	.D.	2,274.55	102.75	1,375.24	31.84	240.67	4.33	40.29	1.57		
7.02 6.30 2.05 1.83	Me	an excretion rate (%)	57.14	40.17	15.43	6.02	4.53	1.57	1.05	0.39	78.16	48.16
	±S.	D.	7.02	6.30	2.05	1.82	1.17	0.41	0.35	0.21	7.31	7.75

Table 17 Urinary concentration in Series II: BRL 28500 (3.2g, W bolus)

		-	able 17 Uri	nary concentra	ation in Series	Table 1/ Urinary concentration in Series II : BKL 2850U (3.2g, IV bolus)	(3.2g, IV DC				
Z	Time (hr.)	0-2		2-4		4-6		8-9		8-0	
	Item	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA
	Concentration (µg/ml)	11,391.70	562.20	1,725.70	54.40	360.40	10.30	.64.90	2.40		
=	Urine volume (ml)	160.00	00	265.00	00	280.00	 06	310.00		1,015.00	00.
=	Excretion (mg)	1,822.67	89.95	457.31	14.42	100.91	2.88	20.12	0.74	2,401.01	108.00
	Excretion rate (%)	92.09	44.98	15.24	7.21	3.36	1.44	0.67	0.37	80.03	54.00
	Concentration ($\mu g/ml$)	7,153.40	325.00	1,830.10	39.00	573.90	8.40	445.40	6.40	_	
13	Urine volume (ml)	230.00	00	280.00	00	260.00	00	100.00		870.00	00
2	Excretion (mg)	1,645.28	74.75	512.43	10.92	149.21	2.18	41.54	0.64	2,351.46	88.49
	Excretion rate (%)	54.84	37.38	17.08	5.46	4.97	1.09	1,48	0.32	78.38	44.25
	Concentration (µg/ml)	14,544.00	694.90	6,147.30	123.00	2,189.40	25.90	367.70	3.80		
13	Urine volume (ml)	110.00	00	80.00	00	80.00	00	105.00		375.00	00
3	Excretion (mg)	1,599.84	76.44	491.78	1.84	175.15	2.07	38.61	0.40	2,305.38	88.75
	Excretion rate (%)	53.33	38.22	16.39	4.92	5.84	1.04	1.29	0.20	76.85	44.38
	Concentration (Ag/ml)	10,693.50	559.00	6,890.70	162.50	1,113.40	17.20	432.30	7.60		
-	Urine volume (ml)	150.00	00	70.00	00	80.00	00	75.00		375.00	00
14	Excretion (mg)	1,604.03	83.85	482.35	11.38	1 20.68	1.38	32.42	0.57	2,207.87	97.17
	Excretion rate (%)	53.47	41.93	16.08	5.69	2.97	0.69	1.08	0.29	73.60	48.59
	Concentration (µg/ml)	9,938.10	449.60	7,510.00	174.00	2,012.70	29.60	375.80	6.40		
Ļ	Urine volume (ml)	170.00	00	70.00	00	80.00	00	90.00		410.00	00
CI	Excretion (mg)	1 689.48	76.43	525.70	12.18	161.02	2.37	33.82	0.58	2,410.02	91.56
	Excretion rate (%)	56.32	38.22	17.52	6.09	5.37	1.18	1.13	0.29	80.33	45.78
	Concentration (µg/ml)	12,225.60	543.20	7,196.40	172.90	703.30	11.00	170.10	3.40		
7	Urine volume (ml)	135.00	00	70.00	00	250.00	00	230.00		685.00	00
3	Excretion (mg)	1,650.46	73.33	503.75	12.10	175.83	2.75	39.12	0.78	2,369.15	88.97
	Excretion rate (%)	55.02	36.67	16.79	6,05	5.86	1.38	1.30	0.39	78.97	44.48
	Concentration (µg/ml)	8,360.80	493.50	5,150.40	148.00	2,723,40	40.10	378.60	09.9		
17	Urine volume (ml)	170.00	00	100.00	00	82,00	00	135.00		490.00	00
	Excretion (mg)	1,421.34	83.90	515.04	14.80	231.49	3.41	51.11	0.89	2,218.98	102.99
	Excretion rate (%)	47.38	41.95	17.17	7.40	7.72	1.70	1.70	0.45	73.97	51.50
	Concentration (µg/ml)	5,468.50	300.90	3,399.60	100.30	872.60	19.30	386.90	8.80		
9	Urine volume (ml)	265.00	00	165.00	00	265.00	00	120.00		815.00	00
01	Excretion (mg)	1,449.15	79.74	560.93	16.55	231.24	5.11	46.43	1.06	2,287.76	102.46
	Excretion rate (%)	48.31	39.87	18.70	8.27	7.71	2.56	1.55	0.53	76.26	51.23
	Concentration (µg/ml)	10,103.10	522.70	7,580.80	237.00	1,470.20	34.90	387.40	11.50		
01	Urine volume (ml)	155.00		70.00		105.00		92.00		425.00	
e.	Excretion (mg)	1,565.98	81.02	530.66	16.59	154.37	3.66	36.80	1.09	2,287.81	102.37
	Excletion rate (70)	02:50	10:01	2011							

2	Time (hr.)	0-2	2	2-4	4	4-6		8-9		8-0	3
	Item	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA
	Concentration (µg/ml)	4,637.20	213.50	8,289.20	158.80	553.60	7.40	341.80	4.70		
8	Urine volume (ml)	310.00	00	70.	70.00	265.00	0	160.00	00	805.00	00
8	Excretion (mg)	1,437.53	66.19	580.24	11.12	146.60	1.96	54.69	0.75	2,219.17	80.01
	Excretion rate (%)	47.92	33.09	19.34	5.56	4.89	0.98	1.82	0.38	73.97	40.01
	Concentration (µg/ml)	10,781.60	564.60	8,051.10	190.50	1,501.00	30.50	277.00	5.30		
č	Urine volume (ml)	145.00	00	75.	75.00	55.00	0	115.00	00	390.00	00
77	Excretion (mg)	1,563.33	81.87	603.83	14.29	82.56	1.68	31.86	0.61	2,281.57	98.44
	Excretion rate (%)	52.11	40.93	20.13	7.14	2.75	0.84	1.06	0.30	76.05	49.22
	Concentration (µg/ml)	10,688.60	544.30	9,152.50	285.10	1,277.50	28.20	425.20	10.30		
	Urine volume (ml)	140.00	00	70.	70.00	150.00	0	100,00	00	460.00	00
22	Excretion (mg)	1,496.48	76.20	640.68	19.96	191.63	4.23	42.52	1.03	2,371.22	101.42
	Excretion rate (%)	49.88	38.10	21.36	86.6	6.39	2.12	1.42	0.52	79.04	50.72
Me	Mean concentration (µg/ml)	9,665.49	481.12	86.076.98	153.79	1,279.28	21.90	337.76	6.43		
±S.D.	D.	2,826.22	136.35	2,513.27	09.69	734.26	11.14	114.15	2.77		
Me	Mean excretion rate (%)	52.62	39.32	17.79	6.85	5.26	1.40	1.31	0.37	76.98	47.94
40+	_	5	20 6	000	,		,	000		000	•

Table 18 Pharmacokinetics parameter of TIPC in Series II

No.	Dose	A	В	α (1/hr.)	β (1/hr.)	K ₁₂ (1/hr.)	K ₂₁ (1/hr.)	K13 (1/hr.)	T _{1/2} α (hr.)	T _{1/2} β (hr.)	Vd β (L)	TBCL (ml/min)	AUC (hr· µg/ml)
	0.8g	77.99	78.35	17.05	1.02	7.09	9.06	1.93	0.04	0.68	9.03	154.04	81.15
11	1.6g	145.61	131.16	5.73	0.78	1.95	3.13	1.43	0.12	0.89	9.93	129.60	192.90
	3.2g	138.22	252.44	5.61	0.84	1.33	3.92	1.19	0.12	0.83	10.99	152.94	326.93
	0.8g	112.26	63.04	5.63	0.69	2.28	2.47	1.58	0.12	1.00	9.77	112.35	111.26
12	1.6g	160.58	134.22	3.88	0.66	1.21	2.13	1.21	0.18	1.05	9.28	102.20	244.63
	3.2g	249.42	299.63	7.37	0.69	2.55	4.34	1.18	0.09	1.00	9.28	107.41	465.51
	0.8g	86.11	56.41	4.72	0.65	1.75	2.26	1.36	0.15	1.07	10.99	119.01	105.04
13	1.6g	129.71	113.90	4.68	0.68	1.56	2.55	1.25	0.15	1.02	11.30	127.91	195.45
	3.2g	219.88	240.10	7.88	0.70	2.90	4.44	1.23	0.09	1.00	11.56	133.97	373.22
	0.8g	68.60	38.55	2.17	0.69	0.41	1.22	1.22	0.32	1.01	12.45	142.15	87.94
14	1.6g	117.88	110.37	3.92	0.68	1.17	2.25	1.19	0.18	1.02	11.47	129.93	192.42
	3.2g	852.02	277.13	25.79	0.70	16.99	6.86	2.65	0.03	0.98	9.99	117.15	426.80
	0.8g	125.68	57.34	7.80	0.74	3.63	2.95	1.96	0.09	0.93	10.82	133.99	93.29
15	1.6g	190.53	113.64	7.52	0.69	3.36	3.24	1.61	0.09	1.00	11.43	132.11	189.24
	3.2g	262.85	269.10	10.00	0.70	4.00	5.41	1.29	0.07	0.99	10.44	121.35	412.04
	0.8g	90.60	63.72	3.33	0.70	0.94	1.79	1.31	0.21	0.99	9.05	106.17	117.74
16	1.6g	164.69	126.57	4.25	0.69	1.39	2.24	1.32	0.16	1.00	9.77	113.19	220.87
	3.2g	374.83	308.32	12.90	0.67	5.98	6.19	1.39	0.05	1.04	9.15	102.03	490.03
	0.8g	91.45	69.45	3.13	0.61	0.92	1.70	1.12	0.22	1.14	8.60	87.19	143.38
17	1.6g	92.04	134.16	3.02	0.61	0.69	2.04	0.91	0.23	1.13	9.81	100.24	249.41
	3.2g	140.62	271.09	3.30	0.51	0.75	2.35	0.72	0.21	1.36	10.25	86.84	575.75
	0.8g	86.45	72.86	5.40	0.65	1.98	2.82	1.24	0.13	1.07	9.00	97.63	128.03
18	1.6g	152.81	131.31	4.41	0.59	1.54	2.35	1.10	0.16	1.18	9.89	97.03	257.64
	3.2g	290.26	267.87	6.55	0.52	2.66	3.41	1.00	0.11	1.34	10.31	89.19	560.61
	0.8g	208.76	83.51	19.67	1.04	11.14	6.36	3.21	0.04	0.67	7.93	137.10	91.17
19	1.6g	142.49	130.74	5.48	0.79	1.80	3.03	1.43	0.13	0.87	9.91	131.06	190.75
	3.2g	525.75	264.14	11.41	0.71	5.93	4.29	1.90	0.06	0.97	10.10	120.02	416.61
	0.8g	90.76	82.50	3.92	0.63	1.23	2.20	1.13	0.18	1.09	7.72	81.47	153.42
20	1.6g	112.89	166.82	2.95	0.65	0.63	2.02	0.95	0.23	1.07	7.83	84.77	294.90
	3.2g	336.38	393.02	8.50	0.61	3.19	4.86	1.06	0.08	1.14	7.19	72.84	686.39
	0.8g	70.42	40.09	3.18	0.66	0.93	1.57	1.33	0.22	1.05	13.70	150.87	82.86
21	1.6g	135.40	91.15	3.13	0.70	0.85	1.68	1.31	0.22	0.99	12.36	144.03	173.57
	3.2g	207.72	247.85	4.95	0.70	1.49	3.01	1.15	0.14	0.99	10.82	126.68	394.70
	0.8g	97.74	64.48	7.64	0.73	3.29	3.48	1.61	0.09	0.95	10.16	123.89	100.89
22	1.6g	130.02	135.24	6.50	0.71	2.29	3.66	1.26	0.11	0.98	10.04	118.89	210.28
	3.2g	202.23	315.48	5.92	0.68	1.69	3.87	1.04	0.12	1.02	8.86	99.99	500.05
0.0-	Mean	100.57	64.19	6.97	0.73	3.02	3.16	1.58	0.16	0.97	9.94	120.49	108.01
0.8g	\pm S.D.	37.67	14.65	5.63	·0.14	3.16	2.29	0.59	0.09	0.15	1.80	24.15	23.62
1.0-	Mean	139.55	126.61	4.62	0.69	1.54	2.53	1.25	0.16	1.02	10.25	117.58	217.67
1.6g	\pm S.D.	26.18	18.38	1.44	0.06	0.76	0.60	0.20	0.05	0.09	1.21	17.97	36.41
20-	Mean	316.77	283.85	9.18	0.67	4.12	4.41	1.32	0.10	1.06	9.91	110.87	469.05
3.2g	\pm S.D.	199.89	41.60	5.91	0.09	4.38	1.28	0.50	0.05	0.15	1.16	22.34	100.51
		L	l	·									

Table 19 Pharmacokinetics parameter of CVA in Series II

				Tole 15		1	paramet	0. 0.				T	AUC
No.	Dose	A	В	α (1/hr.)	β (1/hr.)	K12 (1/hr.)	K21 (1/hr.)	K13 (1/hr.)	Τ _{1/2} α (hr.)	T1/2β (hr.)	Vd-β (L)	TBCL (ml/min)	(hr•
				(1/111.)	(1/111.)	(1/111.)	(1/111.)	(1/111.)	(111.)	(111.)	(L)	(IIII IIIIII)	μg/ml)
	0.8g	2.37	3.71	6.25	0.98	1.57	4.20	1.46	0.11	0.71	12.25	200.16	4.16
11	1.6g	7.89	1.72	1.81	0.42	0.43	0.67	1.13	0.38	1.66	28.28	196.52	8.48
	3.2g	8.80	9.09	2.39	1.74	0.43	1.58	1.12	0.29	0.94	16.93	208.76	15.97
	0.8g	4.40	3.04	6.44	1.04	2.16	3.25	2.07	0.11	0.66	13.32	231.66	3.60
12	1.6g	11.36	3.11	2.97	0.66	0.78	1.16	1.70	0.23	1.04	17.71	195.84	8.51
	3.2g	15.18	9.48	4.12	0.76	1.30	2.05	1.53	0.17	0.91	16.28	206.58	16.14
	0.8g	3.91	2.29	4.12	0.85	1.21	2.06	1.71	0.17	0.81	16.10	229.27	3.63
13	1.6g	8.62	3.02	3.11	0.73	0.81	1.35	1.69	0.22	0.94	19.78	242.03	6.89
	3.2g	12.77	8.97	4.76	0.87	1.49	2.47	1.67	0.15	0.80	17.71	255.46	13.05
	0.8g	4.62	2.86	5.00	0.90	1.60	2.47	1.83	0.14	0.77	13.53	203.70	4.09
14	1.6g	9.98	4.29	4.25	0.70	1.50	1.77	1.68	0.16	0.99	16.88	196.13	8.50
	3.2g	15.57	11.40	6.34	0.79	2.40	3.14	1.60	0.11	0.87	14.99	197.99	16.84
	0.8g	4.62	2.82	6.37	0.94	2.31	3.00	2.00	0.11	0.73	14.28	224.58	3.71
15	1.6g	9.08	3.09	3.34	0.63	1.06	1.32	1.59	0.21	1.11	20.88	217.84	7.65
	3.2g	13.92	10.27	4.41	0.79	1.38	2.32	1.49	0.16	0.88	15.69	205.70	16.21
	0.8g	4.10	2.83	3.54	0.75	0.99	1.89	1.41	0.20	0.92	13.49	169.63	4.91
16	1.6g	10.27	8.65	8.70	1.17	3.04	4.61	2.21	0.08	0.59	9.97	194.90	8.55
	3.2g	16.38	11.99	4.14	0.71	1.33	2.16	1.36	0.17	0.97	13.51	160.29	20.80
	0.8g	3.19	3.56	3.02	0.73	0.67	1.94	1.14	0.23	0.94	11.54	141.12	5.91
17	1.6g	8.31	8.20	9.33	0.96	3.42	5.12	1.76	0.07	0.72	11.05	177.36	9.40
	3.2g	18.26	10.60	3.50	0.60	1.17	1.67	1.27	0.20	1.15	14.54	146.52	22.75
	0.8g	7.60	3.55	6.81	0.70	3.06	2.65	1.81	0.10	0.98	11.53	135.49	6.15
18	1.6g	7.44	8.58	5.26	0.88	1.49	3.23	1.43	0.13	0.79	10.19	148.68	11.21
	3.2g	15.53	10.57	2.59	0.60	0.68	1.40	1.10	0.27	1.16	14.14	140.69	23.69
	0.8g	4.59	2.73	4.18	0.78	1.32	2.05	1.59	0.17	0.89	13.93	181.41	4.59
19	1.6g	7.33	6.02	4.14	0.92	1.09	2.37	1.60	0.17	0.76	13.09	199.86	8.34
	3.2g	17.37	9.80	4.04	0.70	1.36	1.90	1.48	0.17	1.00	15.03	181.30	18.39
	0.8g	6.02	5.01	9.67	0.96	3.83	4.91	1.89	0.07	0.72	8.92	142.51	5.85
20	1.6g	9.01	6.95	4.21	0.92	1.13	2.35	1.65	0.16	0.75	11.20	172.53	9.66
	3.2g	17.72	11.20	3.23	0.68	0.93	1.67	1.31	0.21	1.02	13.41	151.48	22.01
	0.8g	6.67	2.38	7.64	0.78	3.53	2.58	2.31	0.09	0.89	16.33	212.84	3.92
21	1.6g	9.00	3.12	3.18	0.68	0.91	1.32	1.63	0.22	1.03	19.86	223.47	7.46
	3.2g	24.45	8.26	6.67	0.69	3.07	2.20	2.09	0.10	1.01	18.54	212.82	15.66
	0.8g	3.20	2.85	3.34	0.77	0.83	1.98	1.30	0.21	0.90	13.93	179.08	4.65
22	1.6g	6.35	7.90	10.05	0.97	3.40	6.00	1.62	0.07	0.72	11.76	189.35	8.80
	3.2g	14.52	12.91	5.41	0.72	1.88	2.93	1.32	0.13	0.97	13.48	160.72	20.74
	Mean	4.61	3.14	5.53	0.85	1.92	2.75	1.71	0.14	0.83	13.26	187.62	4.60
0.8g	±S.D.	1.51	0.74	2.01	0.11	1.06	0.96	0.34	0.05	0.11	2.03	34.96	0.93
	Mean	8.72	5.39	5.03	0.80	1.59	2.61	1.64	0.03	0.11	15.89	196.21	8.62
1.6g	±S.D.	1.39	2.59	2.76	0.20	1.07	1.75	0.24	0.09	0.33	5.65		
	Mean	15.87	10.38	4.30	0.20	1.45	2.12	1.45	0.09	0.28		24.40	1.12
3.2g	±S.D.	3.71	1.35	1.34	0.31	0.72					15.40	185.69	18.52
		3.71	1.33	1.34	0.31	0.72	0.53	0.27	0.06	0.11	1.71	34.56	3.38

Table 20 Seru	n concentration	in	SeriesIII	: TIPC	(3.0g,	IV	bolus)
---------------	-----------------	----	-----------	--------	--------	----	--------

Time		r		T	T	T	Γ		T _{1/2}	T _{1/2}	ATIO
(hr.)		1/4	1/2	1	3/2	2	4	6	(α)	(β)	AUC (hr
No.	_,	_, _							(hr.)	(hr.)	μg/ml)
23	403.66	243.89	176.67	118.19	76.01	60.74	20.46	6.69	0.10	1.20	388.56
24	464.23	306.84	233.73	143.11	106.29	78.34	21.00	5.12	0.09	1.02	479.86
25	504.47	325.38	265.95	180.28	129.44	96.16	21.81	6.58	0.06	1.02	556.38
26	423.41	285.60	212.26	165.36	118.45	87.65	29.43	8.67	0.09	1.20	511.50
27	431.62	283.81	250.66	192.37	141.07	104.21	29.27	7.50	0.10	1.08	,570.57
28	305.01	261.57	204.20	140.10	92.42	67.77	16.85	3.55	0.21	0.96	407.85
29	378.08	248.46	184.83	129.47	92-73	74.63	21.33	6.49	0.09	1.15	422.28
30	402.50	351.21	267.23	176.40	128.78	92.46	21.84	5.55	0.17	0.99	541.67
31	464.56	348.42	306.02	187.66	140.05	106.40	32.70	9.61	0.19	1.16	617.86
32	439.89	298.30	282.05	170.87	129.48	93.83	28.58	8.15	0.04	1.11	556.17
33	394.79	288.10	219.87	145.61	96.57	70.20	17.07	4.38	0.11	0.98	439.66
34	436.43	312.47	249.95	170.96	117.86	88.80	21.25	5.89	0.08	1.02	517.70
Mean	420.72	296.17	237.78	160.03	114.10	85.10	23.47	6.51	0.11	1.07	500.83
±S.D.	50.52	35.08	39.60	23.99	21.03	14.66	5.18	1.77	0.05	0.08	72.85
		·									

Table 21 Serum concentration in Series III: CVA-K (0.2g, W bolus)

						1 11 (0.2	g, 14 DOI	43/
Time (hr.)	1/12	1/4	1/2	1	3/2	2	4	6
23	17.07	10.09	8.07	4.54	3.21	2.22	0.73	0.25
24	18.70	11.71	6.27	4.22	2.86	1.98	0.52	0.18
25	23.94	14.46	10.35	5.42	3.38	2.25	0.51	0.14
26	18.26	11.01	6.61	3.84	2.64	1.86	0.41	0.11
27	20.09	14.25	8.78	5.88	4.24	2.80	0.82	0.26
28	17.23	9.77	6.50	3.33	2.00	1.27	0.24	<0.08
29	12.77	7.19	5.94	2.89	2.17	1.31	0.38	0.10
30	20.59	16.49	10.25	6.16	4.59	2.80	0.69	0.21
31	22.15	16.31	9.56	5.57	3.53	2.49	0.61	0.16
32	21.82	14.51	8.10	4.31	2.71	1.91	0.44	0.12
33	20.46	14.68	8.17	4.68	3.10	2.18	0.52	0.15
34	20.78	14.20	7.45	4.34	2.77	1.93	0.52	0.15
Mean	19.49	12.89	8.00	4.60	3.10	2.08	0.53	0.16
<u>±S.D.</u>	2.93	2.88	1.52	1.00	0.76	0.49	0.16	0.06

Table 22	Serum	concentration	in	Series III:	BRL 28500	(3.2g, V)	bolus)	
----------	-------	---------------	----	-------------	-----------	-----------	--------	--

No.	Time(hr.)	1/12	1/4	1/2	1	3/2	2	4	6
	TIPC	314.82	239.46	170.30	108.99	81.67	62.30	18.17	5.52
23	CVA	22.17	12.74	8.26	5.64	3.40	2.42	0.88	0.30
	TIPC	374.55	291.84	212.14	145.96	99.55	69.04	15.82	4.31
24	CVA	19.10	14.17	8.48	6.17	4.02	2.45	0.75	0.23
	TIPC	416.62	328.28	222.38	156.33	101.08	73.22	18.38	4.65
25	CVA	21.50	14.12	9.64	5.56	3.23	2.01	0.64	0.19
	TIPC	377.41	272.53	216.00	128.14	104.06	79.71	25.35	8.03
26	CVA	18.18	13.22	9.46	5.02	3.15	2.20	0.53	0.16
	TIPC	524.35	356.78	292.44	189.60	146.46	100.67	26.27	6.52
27	CVA	26.79	15.08	11.05	6.53	4.07	2.91	0.80	0.23
	TIPC	388.19	308.80	209.65	140.42	91.97	67.41	15.64	3.27
28	CVA	17.70	10.60	7.46	4.13	2.42	1.61	0.33	0.16
	TIPC	376.92	261.75	183.98	133.23	87.16	62.71	19.18	6.05
29	CVA	17.87	10.09	7.14	3.99	2.25	1.79	0.45	0.11
20	TIPC	458.89	337.52	260.04	171.72	127.28	85.21	26.94	6.97
30	CVA	20.80	14.55	11.49	6.65	4.35	2.82	0.81	0.23
21	TIPC	448.28	308.15	251.52	160.55	122.60	84.63	25.75	7.54
31	CVA	19.57	13.45	9.77	5.76	3.39	2.35	0.64	0.18
32	TIPC	478.04	276.48	212.66	170.78	108.98	78.13	28.99	7.47
32	CVA	22.14	12.85	8.15	4.47	2.70	1.87	0.42	0.11
33	TIPC	341.07	239.51	199.70	135.26	76.76	56.68	14.47	3.84
	CVA	17.44	11.68	8.70	5.28	3.25	2.06	0.61	0.17
34	TIPC	406.62	298.34	217.02	172.11	108.41	76.57	22.87	5.48
J-4	CVA	18.96	13.70	9.62	5.56	3.09	2.19	0.56	0.16
TIPC	Mean	408.81	293.29	220.65	151.09	104.66	74.69	21.49	5.80
	±S.D.	59.78	37.17	33.40	23.09	20.06	12.19	5.09	1.56
CVA	Mean	20.19	13.02	9.10	5.40	3.28	2.22	0.62	0.19
	±S.D.	2.69	1.54	1.33	0.87	0.64	0.39	0.17	0.05

独で(0.18, 1.03) 時間であった。以上のように TIPC と CVA の血中動態は合剤投与, 単独投与にかかわらず ほぼ同等であった。

尿中排泄においても、合剤および単独投与ともに類似したものであった。すなわち、尿中濃度は TIPC, CVA ともに $0\sim2$ 時間が最高で、合剤の TIPC $11,433.29~\mu g/ml$, 単剤の TIPC $10,611.50~\mu g/ml$ であり、また合剤の CVA $583.58~\mu g/ml$, 単剤の CVA $523.51~\mu g/ml$ と類似していた。また、 $0\sim8$ 時間の尿中回収率をみると合剤の TIPC 74.67%, 単独の TIPC 79.33% であり、また合剤の CVA 49.42% という結果が

得られた。

III. 考 察

BRL 28500 は英国 Beecham 社 が 開発 した 注射 用 penicillin 系抗生物質で、現在広く使用されているTIPC に β -lactamase 阻害剤である CVA を配合した合剤である。英国では既に Benner® らが健常人において、薬力学と組織移行を検討して、その安全性等が確認されている。

BRL 28500 の臨床評価を我が国で始めるにあたり. 薬剤の安全性、吸収・排泄などの検討を日本人の健康成 人で臨床第一相試験として行った。

Table 23 Urinary concentration in Series III: BRL 28500 (3.2g, IV bolus)

		7	able 63 OIII	Table 23 Utilially collectification in Sciesm : Diversory (3:28, 17 Bottos)	rion III ocures		(0.48, 11 00	lus)			
;	Time (hr.)	0-2	2	2-4	4	4-6	9	8-9	8	8-0	
o Z	Item	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	TYPC	CVA
	Concentration (µg/ml)	7,030.50	380.60	2,408.60	92.60	1,542.60	48.50	560.20	16.30	_	· K.··
-	Urine volume (ml)	195.00	.00	190.00	.00	100.00	00	100.00	00	590.00	00
£3	Excretion (mg)	1,370.95	74.22	457.63	17.59	154.26	4.85	58.82	1.71	2,041.66	98.37
	Excretion rate (%)	45.70	37.11	15.25	8.80	5.14	2.43	1.96	0.86	90.89	49.19
	Concentration (µg/ml)	15,734.20	725.70	6,739.70	226.70	978.00	29.90	162.10	5.70		
7	Urine volume (ml)	100.00	.00	73	73.00	137.00	00:	236.00	00	546.00	00
7.7	Excretion (mg)	1,573.42	72.57	492.00	16.55	133.99	4.10	38.26	1.35	2,237.66	94.56
	5	52.45	36.29	16.40	8.27	4.47	2.05	1.28	0.67	74.59	47.28
	Concentration (µg/ml)	10,904.30	540.20	1,468.40	36:20	812.50	19.80	315.30	7.00		
	Urine volume (ml)	142.00	.00	295.00	.00	158.00	00:	123.00	00	718.00	00
53	Excretion (mg)	1,548.41	76.71	433.18	10.68	128.38	3.13	38.78	0.86	2,148.75	91.38
	Excretion rate (%)	51.61	38.35	14.44	5.34	4.28	1.56	1.29	0.43	71.62	45.69
	Concentration (µg/ml)	14,881.00	841.40	8,243.80	192.50	3,517.30	47.90	695.90	8.20		
8	Urine volume (ml)	06	00.06	65	65.00	92	65.00	92.	92.00	312.00	00
3	Excretion (mg)	1,339.29	75.73	535.85	12.51	228.62	3.11	64.02	0.75	2,167.78	92.11
	Excretion rate (%)	44.64	37.86	17.86	6.26	7.62	1.56	2.13	0.38	72.26	46.05
	Concentration (µg/ml)	10,759.10	544.90	1,428.10	39.90	1,720.20	41.00	445.80	10.90		
Ş	Urine volume (ml)	145.00	.00	395.00	.00	95	95.00	110.00	.00	745.00	00.
17.	Excretion (mg)	1,560.07	79.01	564.10	15.76	163.52	3.90	49.04	1.20	2,336.63	98.66
	Excretion rate (%)	52.00	39.51	18.80	7.88	5.45	1.95	1.63	09.0	77.89	49.93
	Concentration (µg/ml)	4,390.40	191.10	5,247.20	88.80	1,761.00	26.10	343.80	4.90		
	Urine volume (ml)	365.00	.00	100.00	.00	82	82.00	100	100.00	647.00	00.
 83	Excretion (mg)	1,602.50	69.75	524.72	8.88	144.40	2.14	34.38	0.49	2,306.00	81.26
	Excretion rate (%)	53.42	34.88	17.49	4.44	4.81	1.07	1.15	0.25	76.87	40.63
	Concentration (µg/ml)	12,754.70	650.20	9,943.40	226.70	2,311.10	39.40	445.50	7.80		
S	Urine volume (ml)	115.00	.00	55	55.00	80	80.00	130	130.00	380.00	.00
R)	Excretion (mg)	1,466.79	74.77	546.89	12.47	184.89	3.15	57.92	1.01	2,256.48	91.41
	Excretion rate (%)	48.89	37.39	18.23	6.23	6.16	1.58	1.93	0.51	75.22	45.70
	Concentration (µg/ml)	15,490.80	823.10	7,073.40	193.90	1,124.60	29.60	235.70	09.9		
	Urine volume (ml)	102.00	.00	06	90.00	62	62.00	220	220.00	474.00	00.
္က	Excretion (mg)	1,580.06	83.96	636.61	17.45	69.73	1.84	51.85	1.45	2,338.25	104.69
	Excretion rate (%)	52.67	41.98	21.22	8.73	2.32	0.92	1.73	0.73	77.94	52.35

Table 23-2

;	Time (hr.)	0-2	2	2-	2-4	4-6	9	8-9	8	8-0	8
o O	Item	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA	TIPC	CVA
	Concentration (µg/ml)	15,285.90	780.00	8,905.30	259.80	2,972.40	08.99	915.30	19.20		
7	Urine volume (ml)	100.00	.00	28	58.00	20	50.00	40	40.00	248.00	00
31	Excretion (mg)	1,528.59	78.00	516.51	15.07	148.62	3.34	36.61	0.77	2,230.33	97.18
	Excretion rate (%)	50.95	39.00	17.22	7.53	4.95	1.67	1.22,	0.38	74.34	48.59
	Concentration (µg/ml)	10,151.30	463.00	6,283.50	133.40	2,426.60	32.30	06.775	7.50		
	Urine volume (ml)	145.00	.00	8	80.00	80	80.00	82	85.00	390.00	.00
25	Excretion (mg)	1,471.94	67.14	502.68	10.67	194.13	2.58	57.62	0.64	2,226.37	81.03
	Excretion rate (%)	49.06	33.57	16.76	5.34	6.47	1.29	1.92	0.32	74.21	40.51
	Concentration (µg/ml)	13,413.60	688.50	2,486.70	06.99	1,814.60	49.10	459.70	12.70		
	Urine volume (ml)	120.00	00:	185.00	00.	73	73.00	02	70.00	448.00	90.
	Excretion (mg)	1,609.63	82.62	460.04	12.38	132.47	3.58	32.18	0.89	2,234.32	99.47
	Excretion rate (%)	53.65	41.31	15.33	6.19	4.42	1.79	1.07	0.44	74.48	49.73
	Concentration (µg/ml)	6,403.90	374.30	2,736.50	68.30	939.40	19.20	379.30	7.40		
	Urine volume (ml)	260.00	.00	173.00	00:	185.00	.00	115	115.00	733.00	.00
45	Excretion (mg)	1,665.01	97.32	473.41	11.82	173.79	3.55	43.62	0.85	2,355.84	113.54
	Excretion rate (%)	55.50	48.66	15.78	5.91	5.79	1.78	1.45	0.43	78.53	56.77
Mea	Mean concentration (μg/ml)	11,433.29	583.58	5,247.05	135.47	1,826.69	37.47	469.71	9.52	1	I
±S.D.	D.	3,861.47	203.39	3,043.59	80.34	846.97	14.02	213.15	4.43	1	1
Mea	Mean excretion rate (%)	50.88	38.84	17.07	6.73	5.16	1.64	1.56	0.49	74.67	47.71
+S.D.	D.	3.25	3.92	1.85	1.46	1.33	0.40	0.36	0.20	3.01	4.56

Table 24 Urinary concentration in Series III: TIPC (3.0g, IV bolus)

No.	Time (hr.)	0-2	2-4	4-6	6-8	0-8
	Concentration (µg/ml)	6872.00	1,868.60	1,117.90	300.50	
	Urine volume (ml)	235.00	280.00	150.00	220.00	885.00
23	Excretion (mg)	1,614.92	523.21	167.69	66.11	2,371.92
	Excretion rate (%)	53.83	17.44	5.59	2.20	79.06
	Concentration (µg/ml)	6,918.50	1,438.90	461.10	203.70	
	Urine volume (ml)	258.00	353.00	328.00	204.00	1,143.00
24	Excretion (mg)	1,784.97	507.93	151.24	41.55	2,485.70
	Excretion rate (%)	59.50	16.93	5.04	1.39	82.86
	Concentration (µg/ml)	11,050.50	2,032.40	903.10	408.40	
	Urine volume (ml)	160.00	255.00	185.00	105.00	705.00
25	Excretion (mg)	1,768.08	518.26	167.07	42.88	2,496.30
	Excretion rate (%)	58.94	17.28	5.57	1.43	83.21
	Concentration (µg/ml)	14,961.20	9,956.70	4,123.50	841.60	
	Urine volume (ml)	110.00	60.00	60.00	90.00	320.00
26	Excretion (mg)	1,645.73	597.40	247.41	75.74	2,566.29
	Excretion rate (%)	54.86	19.91	8.25	2.52	85.54
	Concentration (µg/ml)	12,177.70	1,683.20	1,932.90	328.30	
	Urine volume (ml)	125.00	345.00	100.00	115.00	685.00
27	Excretion (mg)	1,522.31	580.70	193.29	37.75	2,333.9
	Excretion rate (%)	50.74	19.36	6.44	1.26	77.80
	Concentration (µg/ml)	4,955.90	2,578.20	1,167.90	169.90	11.00
	Urine volume (ml)	325.00	215.00	125.00	190.00	855.0
28	Excretion (mg)	1,610.67	554.31	145.99	32.28	2,343.2
	Excretion rate (%)	53.69	18.48	4.87	1.08	78.1
	Concentration (µg/ml)	18,479.10	9,605.50	2,977.60	512.90	70.1
	Urine volume (ml)	90.00	55.00	65.00	120.00	330.0
29	Excretion (mg)	1,663.12	528.30	193.54	61.55	2,446.5
	Excretion rate (%)	55.44	17.61	6.45	2.05	2,440.3 81.5
	Concentration (µg/ml)	7,457.70	3,915.30	1,991.00	604.80	01.0
	Urine volume (ml)	215.00	120.00	1	l	490.0
30	Excretion (mg)	1,603.41	469.84	90.00	65.00	2,291.7
	Excretion rate (%)	53.45	15.66	1	39.31 1.31	76.3
	Concentration (µg/ml)	16,711.70		5.97		70.3
	Urine volume (ml)		9,946.50	3,358.70	1,187.90	240.0
31	Excretion (mg)	80.00 1,336.94	45.00	60.00	55.00	240.0
	Excretion rate (%)	44.56	447.59 14.92	201.52	65.33 2.18	2,051.3 68.3
	Concentration (µg/ml)	9,297.30		6.72		00.3
	Urine volume (ml)	170.00	8,250.90 85.00	2,698.30	816.70	460.0
32	Excretion (mg)	1,580.54		110.00	95.00	460.0
	Excretion rate (%)	52.68	701.33	296.81	77.59	2,656.2
	Concentration (µg/ml)	10,759.00	23.38 9,863.30	9.89	2.59	88.5
	Urine volume (ml)	145.00	1	2,810.50	699.70	205.0
33	Excretion (mg)		50.00	50.00	60.00	305.0
	Excretion (ing) Excretion rate (%)	1,560.06	493.17	140.53	41.98	2,235.7
		52.00	16.44	4.68	1.40	74.5
	Concentration (µg/ml) Urine volume (ml)	7,697.00	2,224.70	1,310.80	361.30	005.0
34		205.80	225.00	120.00	125.00	675.0
	Excretion (mg) Excretion rate (%)	1,578.05	500.56	157.30	45.16	2,281.0
M		52.60	16.69	5.24	1.51	76.0
	oncentration (µg/ml)	10,611.60	5,280.35	2,071.11	536.31	_
±S.D.	verstion rate (94)	4,269.00	3,820.55	1,124.78	304.37	
	xcretion rate (%)	53.52	17.84	6.22	1.75	79.3
±S.D.		3.83	2.26	1.51	0.53	5.4

Table 25 Urinary concentration in SeriesIII: CVA-K (0.2g, N bolus)

No.	Time (hr.)	0-2	2-4	4-6	6-8	0-8
	Concentration (µg/ml)	504.00	165.40	47.30	12.90	
	Urine volume (ml)	170.00	95.00	95.00	127.00	487.00
23	Excretion (mg)	85.68	15.71	4.49	1.64	107.52
	Excretion rate (%)	42.84	7.86	2.25	0.82	53.76
	Concentration (µg/ml)	493.50	42.90	27.80	7.30	
	Urine volume (ml)	157.00	315.00	124.00	155.00	751.00
24	Excretion (mg)	77.48	13.51	3.45	1.13	95.57
	Excretion rate (%)	38.74	6.76	1.72	0.57	47.79
	Concentration (µg/ml)	1,076.90	80.30	24.40	7.60	
	Urine volume (ml)	80.00	135.00	105.00	85.00	405.00
25	Excretion (mg)	86.15	10.84	2.56	0.65	100.20
	Excretion rate (%)	43.08	5.42	1.28	0.32	50.10
	Concentration (µg/ml)	632.80	185.60	39.30	7.90	
	Urine volume (ml)	110.00	60.00	72.00	100.00	342.00
26	Excretion (mg)	69.61	11.14	2.83	0.79	84.36
	Excretion rate (%)	34.80	5.57	1.41	0.40	42.18
	Concentration (µg/ml)	366.00	34.30	30.50	11.80	
	Urine volume (ml)	220.00	460.00	135.00	110.00	925.00
27	Excretion (mg)	80.52	15.78	4.12	1.30	101.71
	Excretion rate (%)	40.26	7.89	2.06	0.65	50.86
	Concentration (µg/ml)	402.40	27.20	19.60	4.90	30.00
	Urine volume (ml)	184.00	256.00	60.00	65.00	565.00
28	Excretion (mg)	74.04	6.96	1.18	0.32	82.50
	Excretion rate (%)	37.02	3.48	0.59	0.32	41.25
	Concentration (µg/ml)	469.00	157.00	42.90	6.90	41.23
	Urine volume (ml)	220.00	55.00	60.00		150.00
29	Excretion (mg)	103.81	8.64		115.00	450.00
	Excretion rate (%)			2.57	0.79	115.31
	Concentration (µg/ml)	51.66	4.32	1.29	0.40	57.66
	Urine volume (ml)	403.70	24.20	34.10	14.20	F45 00
30		270.00	100.00	100.00	75.00	545.00
	Excretion (mg) Excretion rate (%)	108.81	2.42	3.41	1.07	115.71
	Concentration (µg/ml)	54.41	1.21	1.71	0.53	57.85
		749.80	201.60	41.50	11.00	007.00
31	Urine volume (ml)	100.00	80.00	70.00	55.00	305.00
	Excretion (mg)	74.97	16.13	2.91	0.61	94.61
	Excretion rate (%)	37.49	8.06	1.45	0.30	47.30
	Concentration (µg/ml)	369.80	82.50	28.60	7.40	
32	Urine volume (ml)	190.00	120.00	75.00	50.00	435.00
	Excretion (mg)	70.26	9.90	2.15	0.37	82.68
	Excretion rate (%)	35.13	4.95	1.07	0.19	41.34
	Concentration (µg/ml)	588.30	208.40	53.10	11.30	
33	Urine volume (ml)	145.00	70.00	57.00	75.00	347.00
	Excretion (mg)	85.30	14.59	3.03	0.85	103.77
	Excretion rate (%)	42.65	7.29	1.51	0.42	51.88
	Concentration (µg/ml)	226.10	27.90	25.80	8.90	
34	Urine volume (ml)	380.00	435.00	100.00	95.00	1,010.00
	Excretion (mg)	85.92	12.14	2.58	0.85	101.48
	Excretion rate (%)	42.96	6.07	1.29	0.42	50.74
	oncentration (µg/ml)	523.51	103.11	34.57	9.34	_
±S.D.		222.35	74.67	10.22	2.83	
	xcretion rate (%)	41.76	5.76	1.47	0.42	49.42
±S.D.		6.10	2.07	0.43	0.18	5.70

Table 26 Pharmacokinetics parameter of BRL28500 and TIPC

				₹	1 4010 70 1114	HITTO WILLOW	to inditional metrics parameter of DIVESOUN and LIFE	מהסקעות זה	o allu lifo				
Z	Drug	4	В	α	В	K ₁₂	K21	K13	$T_{1/2}\alpha$	$T_{1/2}\beta$	θ PA	TBCL	AUC
	ç	4		(1/hr.)	(1/hr.)	(1/hr.)	(1/hr.)	(1/hr.)	(hr.)	(hr.)	(L)	(ml/min)	$(hr \cdot \mu g/ml)$
23	BRL	179.27	198.53	4.11	09.0	1.26	2.44	1.00	0.17	1.16	13.36	132.81	376.47
51	TIPC	326.23	185.37	4.85	0.55	2.02	2.11	1.27	0.14	1.25	13.48	124.39	401.95
2	BRL	154.00	280.15	4.18	0.70	0.94	2.95	1.00	0.17	0.99	9.80	114.79	435.59
	TIPC	297.14	292.68	5.99	0.70	2.13	3.31	1.21	0.12	1.03	9.20	102.78	486.46
76	BRL	205.28	289.34	4.13	0.69	1.06	2.70	1.05	0.17	1.01	9.27	106.41	. 469.87
3	TIPC	412.18	361.26	11.49	89.0	5.08	5.73	1.36	90.0	1.02	7.78	88.02	568.05
90	BRL	208.65	236.15	4.15	0.56	1.30	2.47	0.94	0.17	1.23	11.35	106.15	471.02
3	TIPC	303.96	285.61	8.59	0.58	3.59	4.46	1.12	0.08	1.20	9.80	94.60	528.55
26	BRL	337.41	395.65	10.24	0.68	3.89	5.84	1.20	0.07	1.02	7.17	81.61	612.65
10	TIPC	1253.32	353.41	32.42	0.63	22.73	7.62	2.70	0.02	1.09	7.94	83.88	596.11
86	BRL	174.33	289.95	4.60	0.74	1.11	3.15	1.08	0.15	0.93	9.43	116.74	428.29
3	TIPC	49.93	286.00	3.87	0.73	0.37	3.41	0.83	0.18	96.0	10.16	122.86	406.97
ő	BRL	235.95	216.96	4.39	09.0	1.48	2.41	1.09	0.16	1.15	12.04	120.46	415.09
3	TIPC	268.79	236.19	7.02	09.0	2.89	3.60	1.17	0.10	1.16	11.58	115.58	432.59
9	BRL	217.58	319.39	4.48	0.63	1.22	2.92	0.97	0.15	1.09	8.57	90.45	552.79
8	TIPC	90.44	359.73	3.50	0.70	0.43	2.94	0.83	0.20	1.00	7.94	92.15	542.62
33	BRL	238.02	299.75	5.25	0.61	1.66	3.20	1.01	0.13	1.13	9.16	93.80	533.10
5	TIPC	171.20	345.71	3.68	09.0	0.79	2.66	0.82	0.19	1.16	8.03	79.72	627.24
33	BRL	489.47	282.08	10.69	09.0	5.51	4.29	1.49	90.0	1.16	69.6	96.83	516.35
}	TIPC	339.29	336.69	13.06	0.62	2.67	6.82	1.19	0.05	1.12	8.50	88.07	567.75
33	BRL	153.71	200.22	2.07	99.0	0.33	1.45	0.94	0.34	1.05	12.04	132.09	378.52
3	TIPC	181.77	280.41	4.53	0.70	1.16	3.02	1.04	0.15	1.00	9.73	112.76	443.44
3	BRL	209.17	305.27	7.10	29.0	2.23	4.48	1.05	0.10	1.04	9.23	102.50	487.83
5	TIPC	215.84	334.04	7.40	99.0	2.26	4.76	1.05	0.10	1.02	8.48	92 26	522.16
BRL	Mean	233.57	276.12	5.45	0.65	1.83	3.19	1.07	0.15	1.08	10.09	107.89	473.13
	±S.D.	94.26	56.30	2.60	0.05	1.45	1.17	0.15	0.02	0.00	1.75	16.07	71.73
TIPC	Mean ±S.D.	325.42 310.62	304.76	8.87	0.65	6.11	1.73	0.50	0.12	0.09	9.39	15.36	510.32 75.49

⋖
б
7
an
8
85
Ø
짐
B
er
iet
띭
ar
Ä
ics
et
Ē
9
ıac
E
þa
Д
7
62
ē
ab
Η

$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$					Table		rmacokinetics	s parameter	27 Pharmacokinetics parameter BRL 28500 and CVA	nd CVA			1	
BRL 19.21 7.80 4.19 0.65 1.71 (1/hr.)	, N	Drug	4	ĸ	Ø	В	K12	K21	K13	T1/2@	$T_{1/2}\beta$	Ø PA	TBCL	AUC
BRL 19.21 7.80 4.19 0.55 1.71 1.60 1.43 CVA 11.94 7.06 3.39 0.56 1.16 1.61 1.18 BRL 13.31 9.25 3.35 0.62 1.04 1.74 1.20 CVA 18.40 7.06 5.09 0.63 2.14 1.86 1.71 BRL 16.76 8.44 3.14 0.66 0.92 1.49 1.30 CVA 17.78 8.47 3.08 0.70 0.84 1.50 1.44 BRL 16.69 7.61 5.13 0.71 2.01 2.09 1.44 CVA 16.69 7.61 5.13 0.71 2.01 1.46 1.35 CVA 16.69 7.61 5.13 0.71 2.01 1.46 1.57 BRL 14.46 6.83 4.04 0.69 1.39 1.76 1.77 CVA 10.54 2.24 0.61 <th></th> <th>0</th> <th></th> <th>1</th> <th>(1/hr.)</th> <th>(1/hr.)</th> <th>(1/hr.)</th> <th>(1/hr.)</th> <th>(1/hr.)</th> <th>(hr.)</th> <th>(hr.)</th> <th>(T)</th> <th>(ml/min)</th> <th>(hr·µg/ml)</th>		0		1	(1/hr.)	(1/hr.)	(1/hr.)	(1/hr.)	(1/hr.)	(hr.)	(hr.)	(T)	(ml/min)	(hr·µg/ml)
CVA 11.94 7.06 3.39 0.56 1.16 1.61 1.18 BRL 13.31 9.25 3.35 0.62 1.04 1.74 1.20 CVA 18.40 7.06 5.09 0.63 2.14 1.86 1.71 BRL 16.76 8.44 3.14 0.66 0.92 1.49 1.30 CVA 17.78 8.97 3.08 0.70 0.84 1.50 1.44 BRL 13.40 6.94 2.25 0.63 1.90 1.49 1.30 CVA 16.69 7.61 5.13 0.71 2.01 2.06 1.74 BRL 18.09 10.03 4.26 0.65 1.56 1.74 1.20 CVA 16.69 7.61 5.13 0.71 2.01 2.06 1.46 CVA 16.69 7.61 5.13 0.71 2.01 1.46 1.74 CVA 10.44 0.63 1.25 </td <td>73</td> <td>BRL</td> <td>19.21</td> <td></td> <td>4.19</td> <td>0.55</td> <td>1.71</td> <td>1.60</td> <td>1.43</td> <td>0.17</td> <td>1.27</td> <td>19.41</td> <td>176.60</td> <td>18.88</td>	73	BRL	19.21		4.19	0.55	1.71	1.60	1.43	0.17	1.27	19.41	176.60	18.88
BRL 13.31 9.25 3.35 0.62 1.04 1.74 1.20 CVA 18.40 7.06 5.09 0.63 2.14 1.86 1.71 BRL 16.76 8.44 3.14 0.66 0.92 1.49 1.30 CVA 17.78 8.97 3.08 0.70 0.84 1.50 1.44 BRL 13.40 6.94 2.25 0.63 0.50 1.19 1.20 CVA 16.69 7.61 5.13 0.71 2.01 2.09 1.74 BRL 13.40 6.94 2.25 0.63 1.56 1.74 1.20 CVA 16.69 7.61 5.13 0.71 2.01 1.44 1.27 BRL 14.76 6.83 4.04 0.69 1.39 1.76 1.84 CVA 14.16 7.24 4.51 0.69 1.39 1.76 1.84 BRLH.4.46 6.83 4.04 <	3	CVA	11.94		3.39	0.56	1.16	1.61	1.18	0.20	1.24	22.13	206.80	16.12
CVA 18.40 7.06 5.09 0.63 2.14 1.86 1.71 BRL 16.76 8.44 3.14 0.66 0.92 1.49 1.71 CVA 17.78 8.97 3.08 0.70 0.84 1.39 1.39 CVA 16.69 7.61 5.13 0.71 2.01 2.09 1.44 BRL 13.40 6.94 2.25 0.63 0.50 1.19 1.20 CVA 16.69 7.61 5.13 0.71 2.01 2.09 1.74 BRL 18.09 10.03 4.27 0.61 1.55 2.07 1.74 CVA 18.09 10.03 4.27 0.61 1.55 2.07 1.74 BRL 14.46 6.83 4.04 0.69 1.39 1.69 1.84 CVA 10.54 7.06 7.08 0.75 1.39 1.69 1.84 CVA 10.54 7.06 7.08<	76	BRL	13.31		3.35	0.62	1.04	1.74	1.20	0.21	1.12	17.07	176.63	18.87
BRL 16.76 8.44 3.14 0.66 0.92 1.49 1.39 CVA 17.78 8.97 3.08 0.70 0.84 1.50 1.44 BRL 13.40 6.94 2.25 0.63 0.50 1.19 1.20 CVA 16.69 7.61 5.13 0.71 2.01 2.09 1.74 BRL 20.88 11.00 4.26 0.65 1.56 1.90 1.74 CVA 15.09 10.03 4.27 0.61 1.55 2.07 1.27 CVA 14.16 7.21 4.27 0.61 1.56 1.74 1.77 BRL 14.27 10.49 2.81 0.66 0.69 1.71 1.0 CVA 10.54 7.06 7.03 0.79 2.84 0.69 1.76 1.72 BRL 13.57 10.49 2.81 0.66 0.71 1.70 1.72 CVA 13.57 10.4	* 7	CVA	18.40	7.06	5.09	0.63	2.14	1.86	1.71	0.14	1.11	21.45	23.62	14.91
CVA 17.78 8.97 3.08 0.70 0.84 1.50 1.44 BRL 13.40 6.94 2.25 0.63 0.50 1.19 1.20 CVA 16.69 7.61 5.13 0.71 2.01 2.09 1.74 BRL 20.88 11.00 4.26 0.65 1.56 1.90 1.46 CVA 15.09 10.03 4.27 0.61 1.55 2.07 1.74 BRL 14.27 12.45 10.28 1.07 3.33 5.36 2.06 CVA 14.16 7.21 4.21 0.61 1.39 1.74 1.27 BRL 14.46 6.83 4.04 0.69 1.39 1.74 1.09 CVA 10.54 7.21 4.61 0.69 1.39 1.76 1.16 BRL 13.10 9.43 3.04 0.69 1.06 1.71 1.0 CVA 17.61 9.67 3.47	J.C	BRL	16.76		3.14	99.0	0.92	1.49	1.39	0.22	1.05	16.72	184.28	18.09
BRL 13.40 6.94 2.25 0.63 0.50 1.19 1.20 CVA 16.69 7.61 5.13 0.71 2.01 2.09 1.74 BRL 20.88 11.00 4.26 0.65 1.56 1.90 1.46 CVA 15.09 10.03 4.27 0.61 1.55 2.07 1.27 BRL 14.27 12.45 10.28 1.07 3.93 5.36 2.05 CVA 14.16 7.24 4.51 0.86 1.43 2.09 1.46 CVA 10.54 7.06 7.03 0.79 2.84 3.29 1.69 CVA 10.54 7.06 7.03 0.79 2.84 3.29 1.69 CVA 13.57 10.49 2.81 0.66 0.71 1.60 1.16 BRL 13.10 9.43 3.04 0.68 0.69 1.67 1.72 CVA 10.54 2.81 0.	62	CVA	17.78		3.08	0.70	0.84	1.50	1.44	0.22	0.99	15.37	179.46	18.57
CVA 16.69 7.61 5.13 0.71 2.09 1.74 BRL 20.88 11.00 4.26 0.65 1.56 1.90 1.46 CVA 15.09 10.03 4.27 0.61 1.55 2.07 1.46 BRL 14.27 12.45 10.28 1.07 3.93 5.36 2.05 CVA 14.16 7.21 4.51 0.69 1.43 2.09 1.84 BRL 14.46 6.83 4.04 0.69 1.73 1.69 CVA 10.54 7.06 7.03 0.79 2.84 3.29 1.69 CVA 11.25 2.84 0.69 1.71 1.0 1.69 BRL 13.10 9.43 3.74 0.69 1.71 1.0 CVA 17.64 9.67 3.77 0.69 1.21 1.52 BRL 19.10 7.31 0.69 1.21 1.52 CVA 17.53 <td>3%</td> <td>BRL</td> <td>13.40</td> <td></td> <td>2.25</td> <td>0.63</td> <td>0.50</td> <td>1.19</td> <td>1.20</td> <td>0.31</td> <td>1.10</td> <td>18.69</td> <td>196.95</td> <td>16.92</td>	3%	BRL	13.40		2.25	0.63	0.50	1.19	1.20	0.31	1.10	18.69	196.95	16.92
BRL 20.88 11.00 4.26 0.65 1.56 1.90 1.46 CVA 15.09 10.03 4.27 0.61 1.55 2.07 1.27 BRL 14.27 12.45 10.28 1.07 3.93 5.36 2.05 CVA 14.16 7.24 4.51 0.86 1.43 2.09 1.84 BRL 14.46 6.83 4.04 0.69 1.39 1.76 1.57 CVA 10.54 7.06 7.03 0.79 2.84 3.29 1.69 CVA 13.57 10.49 2.81 0.66 0.71 1.0 1.16 BRL 13.10 9.43 3.04 0.68 0.72 1.42 1.42 CVA 17.64 9.67 3.47 0.69 1.06 1.67 1.42 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.71 CVA 10.58 8.20 3.7	02	CVA	16.69	7.61	5.13	0.71	2.01	2.09	1.74	0.14	96.0	20.16	238.41	13.98
CVA 15.09 10.03 4.27 0.61 1.55 2.07 1.27 BRL 14.27 12.45 10.28 1.07 3.93 5.36 2.06 CVA 14.16 7.21 4.51 0.86 1.43 2.09 1.84 BRL 14.16 7.21 4.51 0.69 1.39 1.76 1.84 CVA 10.54 7.06 7.03 0.79 2.84 3.29 1.69 BRL 12.08 11.25 2.84 0.66 0.71 1.60 1.16 CVA 13.57 10.49 2.81 0.66 0.71 1.60 1.16 BRL 13.57 10.49 2.81 0.66 0.71 1.67 1.42 CVA 17.64 9.67 3.47 0.69 1.21 1.67 1.42 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.71 CVA 17.68 8.20 3	2.6	BRL	20.88	11.00	4.26	0.65	1.56	1.90	1.46	0.16	1.07	14.10	152.54	21.85
BRL 14.27 12.45 10.28 1.07 3.93 5.36 2.05 CVA 14.16 7.21 4.51 0.86 1.43 2.09 1.84 BRL 14.46 6.83 4.04 0.69 1.39 1.76 1.84 CVA 10.54 7.06 7.03 0.79 2.84 3.29 1.69 BRL 11.25 2.84 0.66 0.71 1.60 1.16 CVA 13.57 10.49 2.81 0.66 0.71 1.60 1.16 BRL 13.10 9.43 3.04 0.68 0.82 1.67 1.24 CVA 17.64 9.67 3.47 0.69 1.07 1.42 1.72 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.71 CVA 17.68 8.20 3.75 0.69 1.21 1.52 1.71 BRL 113.79 17.77 2.45 0.	17	CVA	15.09	10.03	4.27	0.61	1.55	2.07	1.27	0.16	1.13	16.39	167.89	19.85
CVA 14.16 7.21 4.51 0.86 1.43 2.09 1.84 BRL 14.46 6.83 4.04 0.69 1.39 1.76 1.57 CVA 10.54 7.08 7.03 0.79 2.84 3.29 1.69 BRL 12.08 11.25 2.84 0.66 0.71 1.60 1.16 BRL 13.57 10.49 2.81 0.66 0.71 1.60 1.16 BRL 13.10 9.43 3.04 0.68 0.82 1.67 1.16 CVA 17.64 9.67 3.47 0.69 1.06 1.67 1.42 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.71 CVA 20.11 7.46 3.75 0.69 1.21 1.53 BRL 19.70 7.77 2.45 0.66 0.57 1.23 1.71 CVA 19.70 7.13 3.95 0.65<	ä	BRL	14.27	12.45	10.28	1.07	3.93	5.36	2.05	0.07	9.65	14.35	256.27	13.01
BRL 14.46 6.83 4.04 0.69 1.39 1.76 1.57 CVA 10.54 7.06 7.03 0.79 2.84 3.29 1.69 BRL 12.08 11.25 2.84 0.66 0.69 1.71 1.0 CVA 13.57 10.49 2.81 0.66 0.71 1.60 1.16 BRL 13.10 9.43 3.04 0.66 0.71 1.60 1.16 CVA 17.64 9.67 3.47 0.69 1.06 1.67 1.42 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.72 CVA 17.64 3.75 0.69 1.21 1.52 1.71 BRL 10.58 13.79 10.26 0.69 1.21 1.53 CVA 17.68 8.20 3.76 0.69 1.25 1.68 Mean 15.08 0.65 1.39 1.52 1.68 <	0	CVA	14.16	7.24	4.51	98.0	1.43	2.09	1.84	0.15	0.81	20.16	287.22	11.61
CVA 10.54 7.06 7.03 0.79 2.84 3.29 1.69 BRL 12.08 11.25 2.84 0.66 0.69 1.71 1.0 CVA 13.57 10.49 2.81 0.66 0.71 1.60 1.16 BRL 13.10 9.43 3.04 0.68 0.82 1.67 1.24 CVA 17.64 9.67 3.47 0.69 1.06 1.67 1.24 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.72 CVA 20.11 7.46 3.75 0.69 1.21 1.52 1.71 BRL 10.58 13.79 10.26 0.95 3.43 6.22 1.53 CVA 17.68 8.20 3.76 0.69 1.25 1.68 Mean 15.08 9.41 4.51 0.66 0.57 1.30 1.43 ±S.D. 3.19 2.25 2.77 0.	00	BRL	14.46	6.83	4.04	0.69	1.39	1.76	1.57	0.17	1.01	21.52	246.25	13.54
BRL 12.08 11.25 2.84 0.66 0.69 1.71 1.0 CVA 13.57 10.49 2.81 0.66 0.71 1.60 1.16 BRL 13.10 9.43 3.04 0.68 0.82 1.67 1.14 CVA 17.64 9.67 3.47 0.69 1.06 1.67 1.42 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.72 CVA 20.11 7.46 3.75 0.69 1.21 1.52 1.71 BRL 10.58 13.79 10.26 0.95 3.43 6.22 1.71 CVA 17.68 8.20 3.76 0.67 1.25 1.53 BRL 13.77 7.77 2.45 0.66 0.57 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 Aban 16.11 8.17 0.15 1.06 0.	3	CVA	10.54	7.06	7.03	0.79	2.84	3.29	1.69	0.10	0.88	24.25	319.35	10.44
CVA 13.57 10.49 2.81 0.66 0.71 1.60 1.16 BRL 13.10 9.43 3.04 0.68 0.82 1.67 1.24 CVA 17.64 9.67 3.47 0.69 1.06 1.67 1.42 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.72 CVA 20.11 7.46 3.75 0.69 1.21 1.52 1.71 BRL 10.58 13.79 10.26 0.95 3.43 6.22 1.71 CVA 17.68 8.20 3.76 0.67 1.25 1.65 1.53 Mean 15.08 9.41 4.51 0.66 1.39 1.52 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 ±S.D. 3.19 2.25 2.77 0.15 1.10 1.65 0.23 ±S.D. 3.04 1.29	30	BRL	12.08	11.25	2.84	99.0	0.69	1.71	1.0	0.24	1.04	14.20	157.35	21.18
BRL 13.10 9.43 3.04 0.68 0.82 1.67 1.24 CVA 17.64 9.67 3.47 0.69 1.06 1.67 1.42 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.72 CVA 20.11 7.46 3.75 0.69 1.21 1.52 1.71 BRL 10.58 13.79 10.26 0.95 3.43 6.22 1.57 CVA 17.68 8.20 3.76 0.67 1.25 1.53 BRL 13.77 7.77 2.45 0.66 0.57 1.30 1.23 CVA 19.70 7.13 3.95 0.65 1.39 1.43 1.43 ±S.D. 3.19 2.25 2.77 0.15 1.10 1.43 1.43 ±S.D. 3.04 1.29 0.69 0.60 0.50 0.23 0.23	3	CVA	13.57	10.49	2.81	99.0	0.71	1.60	1.16	0.25	1.05	14.62	160.96	20.71
CVA 17.64 9.67 3.47 0.69 1.06 1.67 1.42 BRL 19.10 7.91 4.03 0.72 1.34 1.69 1.72 CVA 20.11 7.46 3.75 0.69 1.21 1.52 1.71 BRL 10.58 13.79 10.26 0.95 3.43 6.22 1.57 CVA 17.68 8.20 3.76 0.67 1.25 1.53 BRL 13.77 7.77 2.45 0.66 0.57 1.30 1.23 CVA 19.70 7.13 3.95 0.65 1.39 1.52 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 Ass.D. 3.19 2.25 2.77 0.15 1.10 1.65 0.27 Mean 16.11 8.17 4.19 0.69 0.60 0.50 0.50 0.23	31	BRL	13.10	9.43	3.04	0.68	0.82	1.67	1.24	0.23	1.02	16.20	183.22	18.19
BRL 19:10 7:91 4.03 0.72 1.34 1.69 1.72 CVA 20:11 7.46 3.75 0.69 1.21 1.52 1.71 BRL 10:58 13.79 10.26 0.95 3.43 6.22 1.57 CVA 17:68 8.20 3.76 0.67 1.25 1.65 1.53 BRL 13.77 7.77 2.45 0.66 0.57 1.30 1.23 CVA 19.70 7.13 3.95 0.65 1.39 1.52 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 Mean 16.11 8.17 4.19 0.69 1.47 1.87 1.53 ASD. 3.04 1.29 1.15 0.06 0.50 0.50 0.50	5	CVA	17.64	29.6	3.47	69.0	1.06	1.67	1.42	0.20	1.01	15.21	173.76	19.18
CVA 20.11 7.46 3.75 0.69 1.21 1.52 1.71 BRL 10.58 13.79 10.26 0.95 3.43 6.22 1.57 CVA 17.68 8.20 3.76 0.67 1.25 1.65 1.53 BRL 13.77 7.77 2.45 0.66 0.57 1.30 1.23 CVA 19.70 7.13 3.95 0.65 1.39 1.52 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 Mean 16.11 8.17 4.19 0.69 1.47 1.87 1.53 ASD. 3.04 1.29 1.15 0.08 0.60 0.50 0.50	33	BRL	19.10	7.91	4.03	0.72	1.34	1.69	1.72	0.17	96.0	17.66	211.81	15.74
BRL 10.58 13.79 10.26 0.95 3.43 6.22 1.57 CVA 17.68 8.20 3.76 0.67 1.25 1.65 1.53 BRL 13.77 7.77 2.45 0.66 0.57 1.30 1.23 CVA 19.70 7.13 3.95 0.65 1.39 1.52 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 Mean 16.11 8.17 4.19 0.69 1.47 1.87 1.53 ±S.D. 3.04 1.29 1.15 0.08 0.60 0.50 0.23	3	CVA	20.11	7.46	3.75	0.69	1.21	1.52	1.71	0.18	1.00	17.88	206.81	16.12
CVA 17.68 8.20 3.76 0.67 1.25 1.65 1.53 BRL 13.77 7.77 2.45 0.66 0.57 1.30 1.23 CVA 19.70 7.13 3.95 0.65 1.39 1.52 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 Mean 16.11 8.17 4.19 0.69 1.47 1.87 1.53 ±S.D. 3.04 1.29 1.15 0.08 0.60 0.50 0.23	33	BRL	10.58	13.79	10.26	0.95	3.43	6.22	1.57	0.07	0.73	13.54	214.35	15.55
BRL 13.77 7.77 2.45 0.66 0.57 1.30 1.23 CVA 19.70 7.13 3.95 0.65 1.39 1.52 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 ±S.D. 3.19 2.25 2.77 0.15 1.10 1.65 0.27 Mean 16.11 8.17 4.19 0.69 1.47 1.87 1.53 ±S.D. 3.04 1.29 1.15 0.08 0.60 0.50 0.23	3	CVA	17.68	8.20	3.76	29.0	1.25	1.65	1.53	0.18	1.03	17.59	197.39	16.89
CVA 19.70 7.13 3.95 0.65 1.39 1.52 1.68 Mean 15.08 9.41 4.51 0.71 1.49 2.30 1.43 ±S.D. 3.19 2.25 2.77 0.15 1.10 1.65 0.27 Mean 16.11 8.17 4.19 0.69 1.47 1.87 1.53 ±S.D. 3.04 1.29 1.15 0.08 0.60 0.50 0.23	25	BRL	13.77	7.77	2.45	99.0	0.57	1.30	1.23	0.28	1.06	17.44	190.84	17.47
		CVA	19.70	7.13	3.95	0.65	1.39	1.52	1.68	0.18	1.07	19.32	208.25	16.01
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	BRL	Mean	15,08	9.41	4.51	0.71	1.49	2.30	1.43	0.19	1.01	16.74	195.59	17.44
Mean 16.11 8.17 4.19 0.69 1.47 1.87 1.53 \pm S.D. 3.04 1.29 1.15 0.08 0.60 0.50 0.23		±S.D.	3.19	2.25	2.77	0.15	1.10	1.65	0.27	0.07	0.17	2.43	31.92	2.70
±5.D. 3.04 1.29 1.15 0.08 0.60 0.50 0.23	CVA	Mean	16.11	8.17	4.19	0.69	1.47	1.87	1.53	0.18	1.03	18.71	214.16	16.20
		±5.D.	3.04	1.29	1.15	0.08	09.0	0.50	0.23	0.04	0.11	3.04	47.97	3.16

Fig. 8 Comparison of mean serum concentration following IV bolus administration of either TIPC 3.0 g or CVA-K 0.2 g or 3.2 g of BRL 28500 (n=12)






Fig. 9 Comparison of mean urinary excretion following IV bolus administration of either TIPC 3.0g or CVA-K 0.2g or 3.2g of BRL 28500 (n=12)





シリーズ1 (筋肉内投与) においては BRL 28500 を 1回 0.8g 筋肉内投与したが, 臨床症状および臨床検査

値においてまったく異常は認められなかった。

シリーズ 2 (静注時における dose response) τ は、 BRL 28500 0.8 g, 1.6 g および 3.2 g を 1 回静脈内投与したが、臨床症状および臨床検査値において異常は認められなかった。

シリーズ3(薬剤相互作用)でも薬剤に起因すると思われる異常は認められなかったが、CVA 単独投与時に臨床症状で1例にむくみを伴った紅潮がみられたが、一過性であり、約1.5時間後には消失した。

なお、BRL 28500 は既発売の TIPC と CVA の合剤であり、TIPC の安全性などは充分に確認されている。 CVA はオーグメンチン開発時に経口剤ではあったが、その安全性は既に確認されている⁹。

以上のとおり、今回の健康成人による臨床第一相試験においても、従来の注射用抗生剤と比較して特に問題となる所見も認められず、その安全性が確認され、また血清中移行濃度、尿中排泄とも TIPC 単独投与時と大差がなく、CVA を配合することによる TIPC との相互作用も認められず、抗生剤として充分臨床応用が可能と思われる薬剤である。

文 献

- BROWN, A. G.; D. BUTTERWORTH, M. COLE, G. HANSCOMB, J. D. HOOD, C. READING & G. N. ROLINSON: Naturally-occurring β-lactamase inhibitors with antibacterial activity. J. Antibiot. 29(6): 668~669, 1976
- 中沢 久, 名倉好巳, 中平和男 R. HORTON: BRL 28500(Clavulanic acid-Ticarcillin) の体液 内濃度測定法。Chemotherapy (投稿中)
- 3) 山岡 清,谷川原 祐介共著:マイコンによる薬 物速度論入門。南江堂、東京、1983
- 4) 山岡 清:マイコンによる薬物体内動態解析法。 南江堂,東京,1984
- 5) 渋谷 健, H.P.クメレ編著: 薬物の臨床治験研 究法。理工学社, 東京, 1983
- 6) 白須泰彦, 吐山豊秋編: 毒性試験 ハンドブック。 フジテクノシステム, 東京, 1980
- 7) 花野 学, 梅村甲子郎, 伊賀立二 編:ファーマコキネティックス実験法。ソフトサイエンス社, 東京, 1985
- BENNET, S.; R. WISE, D. WESTON & J. DENT: Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid. Antimicrob. Agents Chemother. 23(6):831~ 834, 1983
- 9) BRL 25000 (Clavulanic acid-Amoxicillin) 論文 特集号。Chemotherapy Vol. 30 (S-2), 1982

PHASE I STUDIES ON BRL 28500 (CLAVULANIC ACID-TICARCILLIN)

----SINGLE INTRAMASCULAR AND INTRAVENOUS ADMINISTRATION-

KENTARO WATANABE, MASARU KOYAMA and FUKUO IIJIMA Department of Internal Medicine, Tokyo Kyosai Hospital

HISASHI NAKAZAWA and KAZUO NAKAHIRA Laboratory, Beecham Yakuhin K. K.

Series I

BRL 28500 0.8 g was administered to ten volunteers by intramuscular injection. The peak serum concentrations of TIPC and CVA were achieved one hour and 45 minutes after administration with values of 23.20 and 1.12 μ g/ml respectively. The urinary excretion rates (0-8 h) of TIPC and CVA were 69.5 and 41.0% of dose. No adverse effect or abnormal laboratory findings were observed.

Series II

BRL 28500 0.8 g, 1.6 g and 3.2 g was administered to twelve volunteers by intravenous injection. Serum concentrations of TIPC and CVA were 118.8 and 5.9 μ g/ml following 0.8 g, 217.7 and 11.1 μ g/ml following 1.6 g, 404.3 and 20.9 μ g/ml following 3.2 g respectively, achieved 5 minutes after administration. AUC's for TIPC and CVA were 105.9, 4.6 and 215.3, 8.6 and 461.2, 18.3 hr· μ g/ml respectively. A dose response between 0.8 g, 1.6 g and 3.2 g BRL 28500 was observed. The urinary excretion rates (0-8 h) of TIPC and CVA were about 76 and 49% respectively. No adverse effect or abnormal laboratory findings were found.

Series III

TIPC 3.0 g, CVA 0.2 g and BRL 28500 3.2 g were administered to twelve volunteers by intravenous injection using the triple cross over method. The serum concentrations of TIPC following administration of TIPC alone and following BRL 28500 were 420.7 and 408.8 μg/ml respectively achieved 5 minutes after administration, while corresponding values for CVA alone and after BRL 28500 were 19.5 and 20.2 μg/ml achieved 5 minutes after administration. There were thus no significant differences when the components of BRL 28500 were administered separately and in combination. These results confirmed that there was no interaction between CVA and TIPC when co-administered as BRL 28500. The excretion rates of TIPC after administration alone and as BRL 28500 were 79.3 and 74.7% corresponding values for CVA were 49.4 and 47.7% respectively. No abnormal laboratory findings were found. One case of facial flushing in the administration of CVA was observed which disappeared about one hour and forty minutes after administration without treatment. No association with the injection of CVA was found.